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ABSTRACT

JONATHAN TY BUTLER. Influencing T Helper Cell Bias in, Autoimmunity. (Under
the direction of NAREN L. BANIK AND CRAIG C. BEESON). Multiple sclerosis
(MS) is an autoimmune disease of the central nervous system (CNS) that affects
approximately 400,000 people in the United States every year and results in
neurological deficits. Inflammatory events associated with MS include activation
of auto-reactive T cells and migration of these and other immune cells into the
CNS, leading to a coordinated attack upon oligodendrocytes and demyelination.
Most current therapies only treat the symptoms of disease, not the cause, which
is still in large part unknown. Therefore, the identification of the etiology of this
complex disease and the development of new therapies is of great importance.
Targeting these T cells by several mechanisms may prove a valuable
strategy for addressing the complex nature of MS. Improvement in clinical signs
has occurred in experimental autoimmune encephalomyelitis (EAE), the animal
model of MS, with the use altered peptide ligands (APLs) as well as calpain
inhibitors.

APLs produced hypersensitivity reactions in clinical trials at high

doses so the hypothesis was formulated that altering these APLs with nonnatural amino acids will improve bioavailability. Calpain is a calcium-mediated
neutral protease involved in many normal physiological as well as pathological
events. We hypothesize that calpain plays a role in several cellular processes
involving T cells including migration as well as subtype bias. Three specific aims
were designed to test these hypotheses. First, that aza-amino acid incorporation
into APLs would

increase protease resistance while preserving antigen

x

recognition.

Next, that calpain is involved with T cell migration, specifically

chemotaxis, as well as, T helper cell bias, by negatively regulating Th2 type cells.
Finally, the combination of APL and calpain inhibitor treatment in an EAE model
will result in a therapy that is more effective at reducing clinical signs at lower
concentrations than either treatment alone.

The data obtained from these

experiments indicated: (1) aza-amino acids increase APL protease resistance,
(2) calpain is involved with T cell chemotaxis, (3) calpain inhibition results in Th2
proliferation and potentiation and (4) combined calpain inhibitor/APL treatment is
effective at reducing clinical signs of EAE; thus suggesting, that combined
therapy is a viable strategy for developing MS treatments.
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CHAPTER ONE

LITERATURE REVIEW AND SIGNIFICANCE

SIGNIFICANCE
Autoimmunity is a consequence of the inappropriate ,activation of the host
immune system that results in a disease state caus~d ,pythe body's own defense
mechanisms. Autoimmune conditions are -the third most costly diseases to treat
in industrial nations of the world, behind only heart disease and cancer.

The

prevalence of autoimmunity is difficult to estimate due to the number and variety
of conditions that the category encompasses; in Denmark alone, a country with a
health registry, it is estimated that upwards of 5% of the population suffers from
some disease burden as a result of an autoimmune condition.
One of these devastating diseases, thought to result from autoimmune
processes, is multiple sclerosis (MS). The tragedy of MS is that it is a disease of
younger individuals typically diagnosed between the ages of 20 and 50 and
affecting upwards of 2.5 million individuals worldwide with about 400,000 cases
in the USA. There are approximately 200 new cases diagnosed in the United
States every week. Estimates suggest that MS results in $9.5 billion in medical
costs and lost productivity each year.
Much has been discovered about MS since it was first identified 150 years
ago, yet it remains a disease of unknowns. The exact cause of the disease, the
initiating factors, who is susceptible and why the disease progresses are all
areas of active investigation. Much has been learned about the immune system
and central nervous system (eNS) by studying this disease but there is still a
long way to go before MS is fully understood and an effective treatment is
discovered that truly treats the disease's cause and symptoms.
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Continued studies of the immune system and the mechanisms involved in
initiation and continuation of disease is therefore required.,' The complexity and
heterogeneity of MS itself allows for many potential area's of study including the
cells that appear to be involved with pathology, the initiation of autoimmune
inflammation, the resolution of disease symptoms, and the initiation and
propagation of repair in damaged tissue. MS has been studied extensively in a
collection of animal models called experimental autoimmune encephalomyelitis
(EAE).

The model is not a completely accurate recapitulation of the disease

course of MS but it does enable focused study of the various components of the
disease so long as the proper animal model is used and the question is properly
restricted. The initiation of the disease is an important area of study. Thus far
treatments based on the target antigens of the autoreactive immune cells have
had mixed results and warrant improvement. One of the main targets is myelin
basic protein (MBP) and therapies based upon its modification to initiate
tolerance or alter the immune response have shown promise, though have yet to
yield any approved therapies. The complex nature of the disease is still bei'ng
uncovered but the calcium (Ca 2+) activated neutral protease calpain is thought to
be involved with disease pathology as a degenerative protease as well as being
involved in signaling and cellular mechanisms related to T cell activation and
migration. The focus of this dissertation is to explore the pathogenesis of MS
and EAE based on the following specific aims:
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AIM 1: To examine the hypothesis that incorporating aza-amino acids into

altered peptide ligands (APLs) of MBP will increase their'protease resistance
while still maintaining bioactivity.
AIM 2: To test the hypothesis that calpain contributes to disease pathology

through its role in
A:

Chemotaxis and Chemokinesis;

B:

Regulating Th bias through proteolytic regulation of the STAT

signaling pathways.
AIM 3: To examine the hypothesis that combined APL and calpain inhibitor

treatment will

be

more

effective

at

blocking

experimental

autoimmune

encephalomyelitis than either treatment alone.

The exploration of these specific aims will add to the knowledge of MS and EAE
by:
RESULT 1: Proving a possible peptide alternative that will aid in the

development of improved therapeutics.
RESULT 2: Elucidating and demonstrating some of the mechanisms by which

calpain inhibitors may be influencing T cells and how that relates to the observed
therapeutic effect in EAE.
RESULT 3: Demonstrating that multi-compound therapeutic treatment targeting

several pathogenic pathways is more effective at lower concentration than single
compound therapy alone.
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LITERATURE REVIEW
Autoimmunity

The mammalian immune system is composed of many organs, cell types,
proteins and effector molecules working in concert to maintain the homeostasis
and functionality of the entire organism. In order to effectively counteract foreign
invaders and disease states the cells have to recognize and respond to a variety
of challenges including microbial and viral proteins, parasites and other nonnative antigens and mutated self molecules that lead to cancer. The immune
system must accomplish this while being able to recognize itself and avoid
triggering autoimmune reactions.

The innate immune system (neutrophils,

macrophages, dendritic cells) normally activates by pattern recognition through
Toll-like receptors (Kawai and Akira 2009). The adaptive immune system (T cells
and B cells) consists of cells that have randomly arranged receptors that must
first pass self tolerance tests during development before being released into the
vasculature (Hengartner et al. 1988; Kappler et al. 1987).
sometimes

these

autoimmunity.

self-recognizing

cells

escape,

potentially

Unfortunately,
leading

to

During autoimmune responses multiple components of the

immune system interact to target the host cells and systems. The innate immune
system can initiate a response that will favor priming of the adaptive immune
system to spread and carry forward an expanding self-directed response. Vice
versa, the adaptive immune system can escape self tolerance by deletion or
regulation and recognize its specific self-antigen and inappropriately initiate an
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immune response using the innate immune system. to reinforce that response
(Lang et al. 2007).
Autoimmunity is a topic as broad as the number of' ~omponents that make
up a functioning immune system.

This dissertatioh and literature review will

focus on the autoimmune aspect of the disease of MS and its animal model EAE.

Multiple Sclerosis (MS)

Multiple Sclerosis (MS) is a heterogeneous autoimmune disease of
unknown origin that affects about 400,000 people in the United States (Anderson
et al. 1992). The disease derives its name from the sclerotic plaques observed in
the CNS (Charcot 1868) that are the result of inflammatory responses and the
hallmark demyelinated lesions. The disease typically follows one of at least four
potential clinical courses. The most common form, affecting about 85% of the
patient population, is a relapsing-remitting course (RRMS) that is characterized
by attacks of neurological deficit followed by periods without symptoms or less
severe symptoms. The majority of these patients eventually develop secondary
progressive MS (SPMS) in which the neurological deficits will progress without
improvement.

Primary progressive MS (PPMS) affects about 150/0 of patients

and results in a progressive neurological decline from onset of symptoms without
relapses.

Progressive relapsing MS (PRMS) features progression from onset

with relapses later in the disease course (Keegan and Noseworthy 2002). MS is
also classified by the clinical severity adding to the complexity of the
classification of multiple sclerosis subtypes.
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These include benign MS,

diagnosed retrospectively, in which patients remain fully neurologically functional
for 15 years after diagnosis (Rovaris et al. 2009) as welt as ,malignant MS, or the
Marburg variant, which is a rare but particularly aggre$shie form of the disease in
which patients demonstrate a rapidly acute cifhicat course (Poser and Brinar
2004).

Other variants have been identified based on various clinical

manifestations and may include alternative immune mechanisms including
Schilder's

1912 diffuse sclerosis,

Balo's disease,

Devic's disease and

Bickerstaff's encephalitis (Poser and Brinar 2004).
The disease can also be classified by the pathology in the CNS lesions
observed from biopsy or autopsy.

In pattern I the inflammatory response is

mostly T cells and macrophages.

Pattern II is characterized by B cells and

autoantibodies. Pattern III is thought to result from a primary oligodendrocytes
dystrophy.

Finally, pattern IV demonstrates considerable oligodendrocyte loss

and is also suggestive of an oligodendrocyte pathology (Lucchinetti et al. 2000).
Most of these patterns share a T cell and macrophage inflammatory response
but the ultimate mechanism for injury seems to vary between individuals
reinforcing the heterogeneity of MS. The pathogenesis and resulting paralysis
observed in MS is thought to result from an inflammatory attack on the myelin
sheath resulting in demyelinated axons and a loss of nervous conduction, axonal
transection and eventually neuronal death.

Continued immune insults and a

failure of proper remyelination by the oligodendrocytes precursor cells leads to
progressive symptoms of MS (Franklin and Ffrench-Constant 2008).
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The etiology of the disease is still unknown but there are thought to be
environmental components that favor autoimmune 'initi,ation' in genetically
susceptible individuals to initiate a MS clinical pat~oJogy.

The geographical

distribution of higher incidence in higher latitudesan'd temperate climates points
to several possible etiologies including vitamin D levels (Ascherio and Munger
2007) and environmental pathogens (Lipton et al. 2007). No single genetic trait
or mutation identified in MS patients that differs from non-diseased individuals
has been identified; instead susceptibility appears to result from a multi-gene
disease profile. The human leukocyte adhesion (HLA) domain is the strongest
susceptibility locus for genetic predisposition to MS. However, a number of other
common genes that have low odds ratios, but in concert may contribute to a
susceptible genetic profile, have also been identified (The International Multiple
Sclerosis Genetics 2007).

The important genetic components consist of the

cytokine domains and receptors IL-7/IL-7R and IL-2/IL-2R (Maier et al. 2009) as
well as the CD58 (De Jager et al. 2009) genes that encode the LFA-3 costimulatory molecule important for enhanced Treg function which may playa role
in immune response.
The initiation of the disease and the profile of susceptible individuals is still
under active investigation but the pathological mechanisms of the disease are
somewhat better characterized. The involvement of autoimmune myelin specific
T cells is fairly well accepted (McFarland and Martin 2007). The mechanism by
which these cells become primed and activated is again somewhat open to
conjecture including genetic susceptibility in individuals with the disease, antigen
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mimicry by an environmental pathogen of myelin protein '(Lipton et al. 2007;
Steiner and Sriram 2007) and the nature of the myelin ,afltigen~· itself. Once the
myelin specific T cells are primed and activated they . enfer the CNS and initiate
and contribute to an autoimmune assault upon the myelin sheath ultimately
resulting in demyelination.

AutoreactiveT cells appear to be key in the

pathogenesis but there is also involvement of the innate immune system (O'Brien
et al. 2008) as well as the B cell branch of the adaptive immune response and
the complement system (Nikbin et al. 2007).
Most of the current approved therapies for MS attempt to decrease the
inflammatory state (corticosteroid therapy,

interferon-~)

or target the T cells by

decreasing their numbers (cyclophosphamide, mitoxantrone), modifying the T
cell phenotype somehow (glatiramer acetate), or denying the cells entry to the
eNS (natalizumab) (Wiendl et al. 2008). Glatiramer acetate is the only approved
therapy that is thought to result in immune modulation by mimicking a variety of
myelin antigens but the precise mechanism of action is still unknown (Schrempf
and Ziemssen 2007).

Improved targeting of therapeutics, reduction of side

effects and development of therapeutics that treat the disease itself instead of
just the symptoms are all desired goals. The complexity and heterogeneity of
MS, the unknown etiology and the shortcoming involved with the current
treatments all warrant further investigation. No spontaneous animal models exist
for MS, hence making it difficult to study in a true recapitulation of the disease
state, however one of the main tools utilized to study MS is the animal model of
EAE. This induced model of immune attack upon the CNS has shed valuable
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insight into the complex interaction of the eNS and the im'mune· system as well
as leading to several of the current approved therapies. ~(g'latlra;mer acetate,
mitoxantrone, natalizumab) available for the treatment" of MS (Steinman and
Zamvil 2006).

Experimental Autoimmune Encephalomyelitis (EAE)

Probably the best animal model of MS is EAE even though it has
shortcomings in accurately modeling human disease. The long history of this
model began in the 1930s with monkeys in order to study vaccine associated
paralysis (Rivers et al. 1933). Since its discovery, EAE has been extensively
studied and has been demonstrated in various animals including marmosets,
guinea pigs, primates, rats, mice, hamsters, dogs, sheep and rabbits (Baxter
2007).

There are two methods to recapitulate the demyelinating pathology

observed in MS; active EAE or passive EAE.

The active model involves

immunizing an animal with one of the following: brain or spinal cord homogenate,
purified myelin, myelin proteins and most recently the antigenic sequence of the
myelin

proteins

homogenized

mycobacterium (Gold et al. 2000).

with

complete

Freud's

adjuvant

and

The mycobacterium acts as an adjuvant

though multiple toll like receptors and plays a role in priming autoreactive T cells
(Hansen et al. 2006) adding to the notion of the importance of the innate immune
system's recognition of foreign agents in the pathogenesis of EAE and potentially
MS. A pro-inflammatory immune response is then increased by injecting the
animal with pertussis toxin several times (Munoz and Sewell 1984). The role of
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pertussis in the model has been elucidated to include the initiation of the
inflammatory cytokines IL-6, TGF~, and IL-17 which prtme.the~ immune reaction
toward an inflammatory bias (Gijbels et al. 1990; Hdfst~tter et al. 2007) as well as
permeabilize the blood brain barrier (Linthicum et al. ,'1982).
The passive model of EAE involves the immunization of a syngenic donor
animal and then the removal of antigenic cells, typically T cells. The cells are
restimulated with antigen and adoptively transferred into a recipient animal. The
recipient animal will demonstrate the clinical signs of EAE if the transferred cells
are indeed pathogenic and involved with the disease process. This technique
helped identify the role that T helper cells specific to myelin proteins play in the
disease course (Ben-Nun et al. 1981). Depending on the species and genetic
strain of the animals used, clinical signs develop after 9-20 days and involve
spinal cord, brain, optic nerve or all of the eNS (Baxter 2007).
More recently it has been possible to identify EAE models that favor brain
pathology_ This pathology seems to be dependent upon the type of T cell causing
the pathology (Abromson-Leeman et al. 2004) and the ratio of subtypes of T cells
present (Stromnes et al. 2008). There have been many different EAE models to
generate the various profiles of MS including acute monophasic models that only
display the signs once and then are resistant to disease (Swanborg 2001 b),
relapsing remitting models that follow a similar course to RRMS (Brown and
McFarlin 1981) and chronic models that display signs that peak and resolve
somewhat but never return to a baseline level of no disease (Zamvil et al. 1985).
The focus of EAE work has been with T cells due to demonstrated ability to
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transfer EAE pathology, but it is important to recognize that autoantibodies also
playa role in the pathology of MS since anti-myelin antibodles"have' been shown
to exacerbate demyelination in EAE (Schluesener"et aL" 1987). The role of B
cells may be restricted to antigen presentation to T' cells to initiate disease and
not initiate disease themselves with autoantibodies (Bettelli et al. 2006a;
Krishnamoorthy et al. 2006; Ransohoff 2006). Needless to say, understanding
MS is difficult when the animal model is not entirely understood and none of the
identified EAE models perfectly recapitulates MS. Still, various questions can be
addressed depending on the model that is chosen and which component of the
disease is focused upon (Steinman and Zamvil 2006). In fact, variations on the
model are under active development in order to accurately study the various
parameters of MS.

These models will allow for more relevant translation

including the necessary pathogenic cells involved for localization (Stromnes et al.
2008) and the location of the lesions resulting from restricted inflammation (Zhao
et al. 2008).

T cells are still regarded as necessary for the initiation of the

autoimmune response.

Therefore no matter how autoimmunity begins or

progresses, the study of the T cell is a focal point worth investigating.

T CELLS

Development and Subtypes

T cells are leukocytes that develop in the thymus and serve as an
adaptive component of the immune system. These cells develop into a variety of
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subtypes depending on the surface molecules that they display and.the intended
immune challenge that they will encounter. The first dlv~sion: ~is' tHe associated
molecules that aid the T cell receptor (TCR) and divide the cells into CD8+
cytotoxic T cells and CD4+ T helper cells. The CDS.f: cytotoxic T cells recognize
antigen presented on major histocompatibility complex (MHC) class I molecules.
The MHC class I molecules are present on all cells in the body, and allow the
CDS+ T cells to target intracellular pathogens.

The CD4+ T helper (Th) cells

recognize antigen presented on MHC class II molecules.

The MHC class II

molecules are only present on antigen presenting cells (APes) which allows the
CD4+ T cells to target extracellular pathogens by assisting other immune cells
such as B cells and macrophages.

Th cells also assist in innate immune

responses through cytokine secretion and serve as memory cells to preserve the
immune history and prepare for future challenges (Janeway et al. 1997). CD4+
Th cells are further subdivided by the cytokines they secrete and role they play in
the adaptive immune response and include Th1, Th2, Th17 and regulatory T
(Treg) cells (Zhu and Paul 2008). The Th1 and Th2 subtypes were first identified
by the cytokine profiles they produced when stimulated, their surface molecule
pattern and their helper function (Mosmann et al. 1986). Subsequently it has
been discovered that Th1 cells utilize interferon (IFN)-y to signal though the
signal transducer and activator of transcription (STAT) 1 (Lighvani et al. 2001)
and induce the transcription factor T-bet (Szabo et al. 2000) during differentiation
of the subtype. Following differentiation the Th1 response is amplified through
interleukin (IL)-12 signaling which utilizes STAT4 to direct IFN-y production and
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increase inflammation without the TCR, and indepenttent of . the antigen
(Thierfelder et al. 1996).

The Th1 subtype favors ir1'ftarrU'r:aUon~ and assists

macrophages and other inflammatory cells. The Th2.. SUbtype was found to be
dependent upon IL-4 signaling though STAT6 (Zhu et al. 2001) and the
transcription factor GATA-3 (Zheng and Flavell 1997). This pathway is required
for differentiation and increases IL-4 production necessary for autocrine
signaling. The Th2 subtype assists in B cell production of antibodies and also
secretes cytokines that counteract the inflammatory subtypes (Mosmann et al.
2005).

Recently several more distinct subtypes have been identified of which

Th17 cells playa role in inflammation and autoimmunity once associated with
Th1 subtypes (Harrington et al. 2005).

The Th17 cell is differentiated by

stimulation of TCR in the presence of IL-6 and TGFJ3 (Bettelli et al. 2006b;
Mangan et al. 2006; Veldhoen et al. 2006) leading to production of IL-23 which
acts through STAT3 (Mathur et al. 2007) to activate the transcription factor
RORyt (Ivanov et al. 2006). Th17 cells remain a very active area of research.
The other most recently identified subtype is the inducible Treg cells (iTreg)
which serves to regulate the immune response by suppressing the immune
system once the challenge has passed (Sakaguchi 2004). The iTreg cells utilize
TGFJ3 and IL-2 to drive STAT5 (Yao et al. 2007) to activate the transcription
factor Foxp3 (Fontenot et al. 2003) which reinforces the profile.

Figure 1

summarizes the various subtypes by immune role, hallmark cytokine and
transcription factors.

During development, these cells are screened in the

thymus against recognizing self antigen too strongly in order to prevent
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autoimmune reactions (Kappler et al. 1987).

This mechanism does not

completely eliminate self-reactive T cells, which are":-fovlJ,Dd 'in' both normal
individuals as well as patients with autoimmunity (Va!:l"Parijs 'and Abbas 1998).
When the cells do not properly gain self-tolerance the role of preventing
autoimmunity falls to the iTreg cell (Sakaguchi 2004). The various subtypes play
different roles in MS and EAE. While the complete picture is not yet understood,
it is beneficial to review what is known at this point.
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Figure 1: Th Cell Subtypes. The hallmark cytokines and transcription factors
that bias the various subtypes of CD4+ Th cells during development from a
common precursor cell (Zhu and Paul 2008).
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Role of T Cells in MS and EAE

:

The classic view of T cell involvement in

.

MS" ~aocf'EAE

was that

inflammatory CD4 + Th 1 cells specific for MBP of o!ns'.r'myelin proteins were
improperly activated and resulted in the myelin attack and subsequence
l

demyelination (Steinman et al. 1995). The identification of an IL-17 secreting
CD4+ T cell subtype that was distinct from Th1 and Th2 subtypes (Harrington et
al. 2005) has opened up a new avenue of study in autoimmunity. The Th17
subtype has been demonstrated to play a primary role in the pathogenesis of
EAE (Komiyama et al. 2006; Langrish et al. 2005).

Since then, a flurry of

research papers on Th17 role in autoimmunity and its normal function of
protection from extracellular bacteria and fungi has been published (Weaver et
al. 2006). The role in EAE is quite well established but the origins of the Th17
cells in humans appears somewhat divergent from the mouse (Romagnani et al.
2009).

Their role in MS is also questionable representing one of the

shortcomings of translation from EAE.

The actual identity of the pathogenic

subtypes involved and how these autoreactive T cells become activated is a topic
of much debate including theories of molecular mimicry (Wucherpfennig and
Strominger 1995), ineffective priming and TCR avidity (McCue et al. 2004). The
cause of the disease is disputed but the notion that there is an imbalance in the
immune response is not.
Conventional theory held that increasing the Th2 cytokine profile would
counteract the Th1 response and reduce the inflammatory events thereby,
preventing the disease state or pushing the inflammatory state into remission
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(Wei et al. 2007). With the discovery of iTreg cells, research switched focus to
o;"C

'"

0

'

~

these cells as the mediators of controlling disregulatedauil';>bnmune responses
o

(Costantino et al. 2008).

.....

Removing the iTreg cells" --results in onset of EAE

(Sakaguchi 2000) demonstrating their importance fo'r proper immune tolerance.
Transfer of iTreg cells has also been shown to decrease other autoimmune
diseases mediated by CD4+ T cells (Sakaguchi 2004). The entire role of iTreg
cells in MS is not yet known but their proper function appears to be important for
self-tolerance. The immunology of MS does not just involve CD4+ T cells but
increasingly CD8+ T cells are being recognized for their role in the CNS
pathology (Zozulya and Wiendl 2008) as well as their capability and involvement
in EAE (Huseby et al. 2001).

The T cells, irrespective of which subtype is

initiating the reaction, enters the CNS and initiates or mediates an autoimmune
attack upon the myelin sheath resulting in demyelination and reduction of action
potential conduction down the axon.

Figure 2 is a visualization of the

pathological progression of autoreactive T cells into the CNS and demonstrates
the attack upon the myelin sheath as well as the roles that other immune cells
play in the pathogenesis targeting myelin.

The various roles that the Th cell

subtypes play in MS and EAE are still actively evolving as more and more
properties and functions are uncovered. The various cytokines that these cells
produce have an influence on the inflammatory environment locally and in the
entire animal. Therefore the secreted cytokines are an important area to explore.
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Figure 2: T Cells in MS. The multiple roles that T cells play in the initiation of
the MS inflammatory cascade following eNS entry as well as the coordination of
myelin degeneration (8aranzini and Hauser 2002).
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Cytokines
Cytokines are proteins produced by various cell~;typ~~jnCluding immune
cells to reinforce the immune profile by autocrinetpa~acrfne signaling. Among
many other actions, cytokines either reinforce an immune response in similar
subtype Th cells or suppress the activation state of Th cell subtypes that would
counteract the immune response thereby reinforcing a specific immune state
(Zhu and Paul 2008). The Th1 cytokines can counteract Th2 and vice versa.
The Th17 cytokines can counteract Treg and vice versa. The subtypes of CD4+
T helper cells were first identified by the different cytokine profiles that they
produced and divided into Th1 and Th2 subtypes (Mosmann et al. 1986). There
is some overlap in subtype production of cytokines, but of the 35 currently known
interleukin cytokines, there are some important trends to point out.
Th1 cells tend to produce IFN-y and IL-12 resulting in a proinflammatory
profile and aid in cytotoxic cell proliferation. Th2 cells produce IL-4, IL-5 and IL13 aiding B cell development and the creation of plasma cells for antibody
production. More recently the cytokine profiles of Treg and Th17 cells have been
elucidated.

Tregs tend to produce IL-10 and

TGF~

resulting in a true anti-

inflammatory profile to induce anergy in the other T cells in the vicinity, thereby
reducing the inflammatory cascade. Th17 cells produce IL-17 and IL-21, IL-23
and favor a proinflammatory profile thought to initiate the pathogenic process
observed in EAE (Dittel 2008). The cytokines produced by these various T cell
subtypes also have an effect on the other cells around them and can direct an
immune response and inform the local cells' behavior.
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IFN-y from Th1 cells was thought necessary to in1tiate EAE. because it
.

:..

~.

"

upregulates MHC class II molecules as well asadh~~,ibn" rl,olecules on
endothelial cells important for T cell migration, how~ver" IFN-y knockout mice
were actually more susceptible to EAE (Ferber et aL' 1996) suggesting it may be
involved with modulating the disease process,. To further complicate matters, in

a clinical trial of IFN-y, half of the patients with MS experienced an exacerbation
of their disease (Panitch et al. 1987). More recent studies have shown that T cell
produced IFN-y recognition by eNS cells may be important for localization of
lesions (Lees et al. 2008). Needless to say, the elucidation of IFN-y's role in MS
is still evolving. The prototypic Th2 cytokines IL-4, IL-5, and IL-13 have been
shown to decrease the EAE clinical disease (Chitnis and Khoury 2003) and
repress the Th1 and Th17 phenotypes (Zhu and Paul 2008).

Some of the

pathogenesis ascribed to Th1 cells is know known to actually be mediated by
Th17 cells that secrete IL-17, IL-6 and tumor necrosis factor alpha (TNFa)
stimulating local cells to actively secrete chemokines and initiate a strong
inflammatory response (Ouyang et al. 2008).

This process normally provides

protection against extracellular bacteria and fungi; however, in autoimmunity the
system allows for activation of self-recognizing cells that coordinate an attack
upon the host system. Finally, the major effector cytokine secreted by Treg cells
is IL-10 (Taylor et al. 2006).

IL-10 appears to function by decreasing antigen

presentation and inflammatory cytokines. The true role of T cell subtypes in MS
is still debated (Romagnani et al. 2009). As important as the profiles of the cells
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present and the cytokines they produce is the actual mecflanisrJ:l by. which they
~

....

.
"

enter the CNS. Therefore, an exploration of T cell mig.ration~i.$)Narranted.

T Cell Migration

Unactivated, na"ive and memory T cells normally reside in the lymphoid
tissue and vasculature and upon antigen recognition initiate an inflammatory
response and counteract foreign challenges.

An activated T cells leaves the

vasculature after it detects an attractant chemokine through receptor recognition.
This migration occurs in several steps through integrins upregulation leading to
rolling on the vasculature walls, adhesion and finally migration between the
fibroblasts that compose the walls of the vessels. The CNS perivascular space
normally has a relatively small number of T cells compared to other tissues
(Norman and Hickey 2005). Inflammatory cell migration into the CNS appears
necessary to initiate and continue the EAE and MS disease state but can occur
without the classical interaction pattern of rolling or tumbling along the vascular
wall (Vajkoczy et al. 2001).

Normal trafficking of T cells through the CNS is

greatly increased during an inflammatory event in MS or a relapse initiating the
destructive cascade that leads to oligodendrocyte targeting and demyelination.
The autoreactive T cells have to interact with their antigen in order for the cells to
become primed and activated and initiate an autoimmune attack. The specific
integrin,

a4~1,

was identified on T cells that binds to vascular cell adhesion

molecule (VCAM)1. This interaction is specific for CNS vasculature and it was
found that EAE was blocked by monoclonal antibodies to the a4 unit (Yednock et
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al. 1992). This antibody was humanized and tested in -EAE ~andi MS patients
,

"

.,

before being approved by the FDA in 2004.

Natalizum.8tt"s:'an \a4~1-integrin

blocking monoclonal antibody which functions to ptev~nf T cells from binding to
VCAM1 and blocks them from leaving the vasculature and entering the CNS
(Ransohoff 2007).

There have been problems with this therapy including

progressive multifocal leukoencephalopathy (PML) which brings into question its
safety profile (Koralnik 2006b). An association with increased cytomegalovirus
(CMV) or Borna virus infection with natalizumab (Koralnik 2006b) but the
treatment was associated with JC virus infection (Stuve et al. 2008). PML does
not occur in animals that are used for EAE models so this was an unintended
consequence.

The drug has since been restored to the market albeit with

stringent prescribing guidelines and monitoring requirement (Steinman and
Zamvil 2006).

Blocking migration of pathogenic cells is a logical strategy to

decrease disease symptoms and other therapeutics that employ this strategy yet
have fewer negative side effects may also prove beneficial. The problem with
natalizumab is that it excludes all T cells from the eNS even though maintenance
of non-autoreactive T cells or Tregs migration is probably beneficial.

When

autoreactive T cells do get into the eNS, their major pathological mechanism is a
coordinated attack upon the myelin sheath (figure 2).

Myelin

Myelin is the compound that is the central target of attack in MS and EAE.
Myelin is produced by oligodendrocytes in the eNS and Schwann cells in the

23

PNS (Waksman 1999).

Oligodendrocyte cell membranes"wrap around axons
..
".....

and undergo a process called compaction where the

'-:"'_

-.

....

cytGpla~'m
.

.

,,'

t~

i's squeezed out

in order to produce myelin to provide insulation between" the' nodes of Ranvier
and increases conduction velocity of action potentials (Martenson 1992). Myelin
is composed of 80%

lipids and 20%

proteins, of which several are prominent

antigenic targets in MS and EAE and targets of inflammatory assault. Due to the
unknown etiology of MS and the heterogeneous clinical course, the various
protein and lipid components of myelin have been extensively studied. Attempts
were made to associate specific myelin proteins with the variety of clinical
courses observed (Sospedra and Martin 2005). Myelin basic protein (MBP), is
the most studied autoantigen in MS due to its abundance in the CNS in a specific
isoform.

Myelin oligodendrocyte protein (MOG) is a small protein that is a

component of the outer lamella only found in the CNS and is the most antigenic
of the myelin proteins. Proteolipid protein (PLP) is a myelin protein that is mildly
antigenic in EAE and only a small percentage of MS patients react positively to it.
Myelin-associated glycoprotein (MAG) requires very sensitive tests in order to
detect it and the peptide sequences are only marginally immunogenic
(Andersson et al. 2002). MS patients have been identified with specific T cells
which react to MBP, PLP, MAG and MOG (Soderstrom et al. 1994)
demonstrating the antigenicity of these various myelin components. The
antigenic potential also extends to autoantibodies generation against MBP,
MOG, PLP, and MAG (8aig et al. 1991; Berger et al. 2003; Warren and Catz
1994) which have all been identified in the cerebral spinal fluid (CSF) of MS
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patients. The presence of autoantibodies to myelin proteinS"in normal individuals
points to a more fundamental and elusive mechanism by.'V{hicti'pe~ople
with MS
,
develop neurological deficits (Hedegaard et al. 2008):, . . I'vfsp is found in greater
quantity in the eNS and also a different isoform exists in the eNS which raises
the question of how the peripheral T cells that have escaped self-reactive
deletion become activated in order to enter the eNS (Sospedra and Martin 2005)
and contribute to pathology.

Myelin Basic Protein (MBP)
One of the major components of myelin is MBP and was one of the first
protein targets of autoreactive T cells isolated from MS patients identified
(Richert et al. 1983). Subsequently, a more complex repertoire of reactive T cells
to MBP has been isolated from MS patients and EAE models and the numerous
immunodominant regions which vary by species and strains were identified
(Tabira and Kira 1992). Distinct sequences of the protein are immunodominant
and produce higher levels of antigenicity than other sequences due to the binding
kinetics of the sequences in susceptible human leukocyte antigen (HLA) domains
(Li et al. 2000). The HLA is the human equivalent of the MHC domain in rodents
which presents antigen to T cells.

The antigenic sequences can begin with

distinct sequences of the MBP protein but as the disease progresses the
autoreactive T cells population has the potential to expand its recognition
repertoire, termed epitope spreading, (Goebels et al. 2000) leading to greater
disease burden and expanded inflammation. The interaction between the most
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antigenic sequence and its corresponding MHC class II niolecule is .surprisingly
,

~."

.>.

weak (Nicholson et al. 2005). This suboptimal interactio"n-'rvay~cbntribute to how
k '

J

autoreactive T cells escape deletion in the thymus "durinQ development. Studies
J'.

have long shown that tolerance in MBP. specificT cells can be induced by
treating EAE with the antigenic sequence of MBP and this tolerance relates to
the avidity of the TCR (McCue et al. 2004).
This weak interaction also allows for some degenerative potential for the
sequence of MBP and for manipulation of this antigenic sequence to increase the
binding kinetics of the peptide residues present in the antigenic sequence.
These sequence changes result in an altered peptide ligand (APL) (Karin et al.
1994).

Several therapeutics have been developed from MBP characteristics

including glatiramer acetate (Schrempf and Ziemssen 2007), which is random
polymer composed of the MBP amino acid molar ratio of L-glutamic acid, Llysine, L-alanine and L-tyrosine, as well as several targeted antigens of MBP (K.
G. Warren 2006) and various APLs of the antigenic sequence of MBP (Lutterotti
et al. 2008). The goal of these therapeutics is to treat early in order to reduce the
incidence of relapse, progression and epitope spreading of immunogenic cells.

Altered Peptide Ligands (APLs)

The T cell receptor (TCR) and major histocompatibility complex class II
(MHC II) with a peptide displayed in the binding groove along with accessory
binding molecules form the complex (immunological synapse) (Dustin 2008)
necessary to activate a specific T cell. Inside of this complex lies the peptide, the
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component of a protein processed inside the cell and bound to ,a specific MHC II
molecule, for which a specific TCR will bind. - This-PeRtiqe' i's 'the antigenic
sequence of a target protein. The sequence of thisJ,.pe\.ptide- can be altered to
influence the binding kinetics of the TCR, either increasing or decreasing the
affinity, and thereby alter the response from the target T cell (Karin et al. 1994).
In fact, the TCR can recognize ligand peptides that have no sequence homology
(Hemmer et al. 1998), thus opening the possibility for development of APLs with
no potential for cross reaction.

This altered response can result in immune

modulation and change the default inflammatory response.
The concentration of antigen present also has an influence on the avidity
of the TCR present in a population of T cells with less antigen resulting in a
population with strong avidity for an antigen and more antigen resulting in a
population with a low avidity TCR (Mazzanti et al. 2000).

This observation

demonstrates the importance of bioavailability in APL design and the population
of reactive cells that may result. Antigen specific therapy has been attempted
with a number of myelin protein sequences (Lutterotti et al. 2008). In fact, this
strategy has been employed to alter the disease course of EAE and has also
been attempted in MS patients with altered MBP peptide (Bielekova et al. 2000;
Kappos et al. 2000). These clinical trials were promising but ultimately proved
disappointing when unintended hypersensitivity reactions occurred.

The

hypersensitivity responses were theorized to be due to the development of an
allergy to the APL caused by a shift to a Th2 bias after loss of self tolerance.
Additionally, when the trial was performed again, this time with doses spaced
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farther apart in order to decrease hypersensitivity reaction-so no clirl,ical benefit
was seen above standard therapy (Steinman and Zamvit 2'0(0)
Experiments have shown that it is possible to~.d~,~elop an allergic response
to self antigens. These animals developed myelin'autoreactive antibodies and
an anaphylactic type response following repeated challenge with PLP antigen
after resolution of an initial EAE disease course (Pedotti et al. 2001). The low
bioavailability of the test APL and large frequent doses required for effective
treatment possibly contributed to making the patients sensitized to the APL
(Kappos et al. 2000).

More recently, a phase 2 clinical trial utilizing the

immunodominant sequence of MBP (MBP8298) as a therapy realized significant
results in delayed progression of disease in a subgroup of HLA-DR2 or 4 patients
(Warren et al. 2006).

Trials are currently underway utilizing other antigen-

directed approaches including a DNA vaccine of a plasmid encoding full length
MBP (Garren et al. 2008) and trivalent TCR peptides (Garren et al. 2008) in order
to increase Treg proliferation. The antigen directed approach is still viable and
APLs are the most specific version of this strategy, despite the hypersensitivity
side effects. The APL strategy is not without merit.

CALPAIN

Structure and Substrates

Calpain is a calcium (Ca 2+) activated neutral cysteine protease.

The

existence of a protease activated by Ca 2+ was first identified in rat brain (Guroff
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1964) and since then over 15 subtypes have been identified that are either
ubiquitously expressed or are tissue specific (Suzuki ef~L 2'0(4). The two most
commonly studied subtypes are IJ-calpain and m~calp~ltn (achieving half-maximal
activation with IJM or mM concentration of,Ca 2+ in vitro respectively). These two
calpains are also referred to as calpain 1 and calpain 2, respectively (Ray and
Banik 2002). Throughout this dissertation both will be collectively called calpain.
Calpain is required for normal function and development as it is an
embryonic lethal knockout (Zimmerman et al. 2000).

With regards to

autoimmunity and MS/EAE, calpain activity has been detected in immune cells
as well as in all cells in the CNS, demonstrating its importance for proper
physiological function (Liu et al. 2008; Schaecher et al. 2002). The structure of
IJ-calpain and m-calpain exists as heterodimers composed of a catalytic 80kDa
large subunit and a regulatory 30kDa subunit. The 30kDa subunit is identical for
both isoforms (Suzuki et al. 2004). The large subunit has 3 potential Ca 2+ binding
motifs and the small subunit has 2 potential Ca 2+ binding motifs (Ray and Banik
2002). The crystal structure of IJ-calpain reveals that cooperative calcium binding
is required to allow alignment and activation of the protease (Moldoveanu et al.
2002). Calpain has known signaling functions and is involved in a multitude of
cellular processes including apoptosis (Zhivotovsky et al. 1997), activation
(Penna et al. 1999; Schaecher et al. 2004), cell cycle regulation (Janossy et al.
2004) and migration (Butler et al. 2009; Franco and Huttenlocher 2005;
Huttenlocher et al. 1997). Calpain activation state is controlled endogenously by
intracellular Ca 2+ levels and its associated endogenous inhibitor, calpastatin
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(Emori et al. 1987). Increasing Ca 2+ level leads to autocaf~"'ytic act~vation of the
subunits for which calpastatin serves the purpose of countera¢ting in a regulatory
manner (Takano and Murachi 1982). Calpastatin

h~as

proved useful in the study

of calpain in regards to knockout animal techniques. 'In order to study the effects
of a calpain knockout (embryonic lethal) without actually knocking out the protein,
a transgenic was developed that overexpressed the endogenous inhibitor of
calpain, calpastatin (Higuchi et al. 2005).

This model has been used to

demonstrate the importance of calpain in CNS inflammatory pathologies. Due to
the many cellular functions that calpain participates in, effective exogenous
inhibitors would prove useful.

Synthetic Inhibitors

Since the identification of calpain as an important protease involved with
multiple signaling and effector functions in a variety of cell types the desire to
develop effective and specific inhibitors has existed. The endogenous inhibitor
calpastatin is too large to be an effect drug molecule. Therefore, two potential
strategies were employed in the development of effective calpain inhibitors: (1)
target the active site by covalently binding to the cysteine residue; (2) indirectly
target the protease by preventing Ca 2+ binding to inhibit the conformational
changes that opens the active site. The first inhibitors were epoxides derived
from aspergillus (Sugita et al. 1980) but had the problem of cross reactivity with
papains and cathepsins. The peptidyl aldehyde type inhibitors were first isolated
from actinomycetes as leupeptins but also inhibited serine proteases (Aoyagi et

30

al. 1969). Additionally, these early compounds had the problem- of poor cellular
permeability.

The aldehydes were improved with tne~ ~y~th~sis, of the cell

permeable inhibitor calpeptin (Tsujinaka et al. 1988).' Unfortunately, these early
peptidyl aldehydes have an extremely short half-life in vivo (Wang and Vuen
1997). Effort has been made to improve the bioavailability of the inhibitors by
synthesizing

non-peptide

based

compounds.

Compounds

based

on

quinolinecarboxamide scaffolds have demonstrated effective inhibition of IJcalpain (Graybill et al. 1995) as well as xanthene derived aldehydes, aketocarboxamides and fluoromethlketones (Chatterjee et al. 1996).

Selective

inhibitors that target the Ca2+ binding sights based on a-mercapto acrylic acid
derivatives have been developed that are extremely selective (Wang et al. 1996).
Historically, the largest obstacles for developing an effective calpain inhibitor as a
therapeutic

have

been

the

solubility,

effective

half-life

and

membrane

permeability. However, recent advances in the design of calpain inhibitors has
increased all of these parameters to the point where an effective orally available
inhibitor is now developed (Shirasaki et al. 2005; Shirasaki et al. 2006). This
inhibitor based on a peptidyl a-ketoamide greatly reduces the side reactions that
peptidyl aldehydes undergo while maintaining potency in the active site (Cuerrier
et al. 2006).

Physiological and Pathological Function in MS/EAE
Calpain disregulation has the potential to either be the cause or
consequence of pathological states given its regulatory role in cellular processes.
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Increased calpain activity has been demonstrated in infilfrating.:monocytes into
the CNS during the disease state of EAE (Schaecher 'et"at:,;~2002) as well as
increased activity observed the peripheral blood m6noc,yfe
cells (PBMC) isolated
".
,

.....

from MS patients in a relapse state (Imamet aL 2007). Calpain degrades MBP
(Banik et al. 1994) and PLP (Ray et al. 2003b) producing the antigenic fragments
to which autoreactive T cells from EAE animals and MS patients react
(Deshpande et al. 1995). The general inflammatory state in the CNS during a
relapse favors calpain activation which drives a Th1 profile as well as increases
in native glial cells leading to dysfunction and adding to the pathological state
(Shields et al. 1999b). Calpain is upregulated in the inflammatory cells of the
spleen before clinical signs of EAE adding evidence to its role in either T cell
priming or initial activation (Shields et al. 1999a). Calpain seems to be correlated
to the Th1 subtype and negatively correlated to the Th2 subtype (Imam et al.
2007). Calpain also plays a role in the pathogenesis of EAE as treatment with
calpain inhibitors blocks the clinical signs of the disease (Guyton et al. 2006;
Hassen et al. 2006).

The role that calpain plays in the neurodegeneration

observed during EAE (Hassen et al. 2008) has also been extensively studied in
our lab.
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CHAPTER TWO

AZAPEPTIDE INCORPORATION INTO
ALTERED PEPTIDE LIGANDS

INTRODUCTION
CD4+ T helper cell activation and response is a'''critica,tcbmponent of an
effective mammalian immune system. Normal development of the CD4+ T cell in
the thymus requires recognition of antigen. presente.a in the context of a MHC II
molecule on the surface of an APC.

Deletion of non-responsive, as well as

hyper-responsive cells, contributes to preventing autoreactive T cells from
entering the body, reducing the potential for self recognition and autoimmunity.
While T cells that recognize self proteins do exist in the circulation of normal
individuals (Mazzanti et al. 2000) autoimmunity due to inappropriate T cell
activation does occur, either through antigen mimicry (Greene et al. 2008), low
affinity antigen (McCue et al. 2004) or T cell escape (Kawamura et al. 2008).
While the exact etiology of MS is unknown, it is thought that the pathology is
largely due to activation of self-reactive T cells against myelin antigens and the
initiation of an inflammatory response in the CNS resulting in demyelination
(Keegan and Noseworthy 2002). The involvement of T cells responsive to myelin
proteins is a mechanism elucidated with and more easily demonstrated in the
animal model of MS, EAE (Baxter 2007).
Therapies based upon altering the inappropriate T cell response through
targeting antigen presentation is possible (Kappos et al. 2000; Karin et al. 1994;
Leadbetter et al. 1998). Changing the antigenic peptide's sequence to influence
binding kinetics can alter the response of autoreactive T cells (Rabinowitz et al.
1997).

These changes result in APLs.

APLs of MBP have been effective at

reducing the clinical disease of EAE (Karin et al. 1994; Smilek et al. 1991) but
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trials in MS patients uSing the same methodology proved 'disappointing
(Bielekova et al. 2000; Kappos et al. 2000). The high ctose.s,,(eql.lired to achieve
clinical benefit proved problematic due to hyperser1sithLity responses in some of
.

J'\t~

the test subjects. A subsequent trial was .attemptett with a reduced dose and
reduced treatment frequency but no therapeutic benefit was observed (Steinman
and Zamvil 2006).

Optimization and improvements to the APL to increase

bioavailability prior to human testing may have proved beneficial and resulted in
a more favorable therapeutic outcome.
The TCR/MHC II complex is specific for the antigens that it will bind, but
does demonstrate some degree of degenerative binding with regard to the
peptide sequence that will interact within the binding groove (Smilek et al. 1991).
Once the TCR and MHC II contact points have been identified, it is possible to
perform logical substitutions to the native peptide sequence to alter the
properties of the ligand in order to either increase or decrease binding (Matsui et
al. 1994). Figure 3 is based on the molecular model (Lee et al. 1998) of the MBP
Ac1-9 peptide binding to the I_Au MHC II and gives an idea of where the
residue/peptide contacts the TCR and MHC II. The contact points of the MBP
Ac1-9 peptide to the I_Au MHC II molecule and 172.10 TCR were confirmed a few
years later by the crystal structure (He et al. 2002) (Figure 4).

Structural

modifications can be performed to also alter the peptide's biokinetic profile
including solubility and protease resistance.
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Figure 3: MBP Presented to a T cell. A representative drawing of the MBP
Ac1-9 peptide binding to the I_Au MHC II molecule and the 172.10 TCR.
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Figure 4: MBP Binding to MHC II. The crystal structure of MBP Ac1-11 binding
to the I_Au MHC II protein confirming the empty P1 pocket (He et al. 2002).
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Peptides in the body, either native signaling peptides or "peptid~s used as
drugs, are subject to degradation by non-specific proteaseS"Qh the cell surfaces
(Boonen et al. 2009).

Therefore, changes to a t'e~!ide sequence in order to

create an APL with increased protease resistance may result in a peptide with
increased bioactivity.

The increased protease resistance may allow for a

reduced dose while still maintaining an immunomodulatory effect ultimately
resulting in an APL with less potential for hypersensitivity side reactions.
The following work sought to address some of the short comings of the
bioavailability recognized in previous APL work (Zaliauskiene et al. 2002). Azaamino acids, an amino acid with nitrogen substituted for the a-carbon, (Figure 5)
were utilized to create APLs and, some of the properties that contribute to
bioavailability were tested. MBP and its interaction with the mouse I_AU MHC II
complex was examined in order to determine if substitution would result in a
peptide that still bound to the specific antigen presentation cleft.

Protease

resistance compared to the native MBP Ac1-9 sequence was also tested.
Finally, the recognition and initiation of an activation response though the TCR
using aza-APLs as the stimulus was determined. Though this study utilizes MBP
as the starting sequence to create APLs, the resulting substitutions with azapeptides are applicable to any situations where immune modulating APLs are a
potential therapeutic and improved bioavailability is desired.
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AZA-PEPTIDE

PEPTIDE

Figure 5: An Aza-Amino Acid. The substitution of the a-carbon in an amino
acid for a nitrogen results in an aza-peptide. These aza-amino acids were
chemically inserted into peptide sequence during synthesis of the APLs.
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APL Sequences and the IL-2 Response.

Name

MBP PeptiCie

IL-2

Sequence

Response

l·tltTl
MBP Ac1-9/4K1Native sequence

Ac-ASQKRPSQR

MBP Ac1-9/5K1Null sequence

Ac-ASQKKPSQR

lt~tt~

MBP Ac1-9/4A/Strong agonist

lTlTfl
1 l TTl

4Y5azaG
4F

2azaG4F

+
++

Ac-ASQYRPSQR

lt
3azaG4Y

+++

Ac-AGazaQARPSQR

lTitfl
MBP Ac1-9/4Y/Agonist

-

Ac-ASQARPSQR

l

2azaG4A

++

l ftl

-

Ac-ASG azaYRPSQR

l t lT fl

-

ltltTl

+++

Ac-ASQYGazaPSQR
Ac-ASQFRPSQR

l

tl Ttl

++

Ac-AGazaQFRPSQR

Table 1: A summary table of the aza-substitutions performed to the native MBP
sequence. The arrows above the native sequence designate the contact points
where down arrows correspond to MHC II molecule contacts and up arrows
correspond to TCR contacts. The IL-2 response is the maximal response from
the T cell activation assay for the various APLs relative to the native sequence.
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MATERIAL AND METHODS

Cell Culture and Reagents
A mouse L929 line of fibroblast like cells tt1af Rave been transfected to
•

JIv,

express I_AU MHC II protein (Tate et al. 1995) an"d a ,,. cell hybridoma (Goverman
et al. 1993) that expresses the 172.10 TCR specific for rat MBP Ac1-11 peptide
were used in the T cell activation studies.

The L929 cells were maintained in

Dulbecco's modified Eagle F12 media (Gibco, Grand Island, NY) supplemented
with 100 U/ml penicillin and 1 J,Jg/ml streptomycin (Gibco) and 10% FCS
(Hyclone, Logan, UT) at 37°C in a 5%

CO 2 atmosphere (Thermo Fisher

Scientific, Waltham, MA) and grown to desired confluency for each of the assays
performed. The 172.10 cells were<h1aintained the same way as the L929 cells
except RPMI 1640 media (Gibco) was used instead of DMEM F12.

Peptide Synthesis and Labeling
Peptide synthesis grade reagents were purchased from Advanced
Chemtech (Louisville, KY) and peptide components were obtained from Peptides
International (Louisville, KY).

The native and altered MBP peptides were

synthesized using rink amide resin (Novabiochem, Darmstadt, Germany) solid
phase Fmoc-HBTU/tert-butyl protection chemistry as previously described (Hart
and Beeson 2001). After synthesis was complete the resin was divided.

Half

was deprotected and cleaved from the resin for the serum degradation and T cell
activation assays and half was fluorescein-labeled before final deprotection and
cleavage for the MHC II binding assay. Peptides were cleaved from the resin by
mixing with 90% trifluoroacetic acid (Sigma-Aldrich Corp. St. Louis, MO), 40/0

41

Tetraiodosilane (Sigma) and 6% water for 3 hours and lnen-c prec,i.pitated with
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diethyl ether (Sigma). The solvent was decanted and d'ried .. fQr~24 hrs under high
~'-

vacuum.
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The peptides were then dissolved in dtrn~~hylsulf6xide (OMSO) and

purified by reverse phase high performance liq"uidchromatography (RP-HPLC)
on an acetonitrile/water gradient (Waters, Milford, MA).

The peptides were

characterized by electrospray ionization mass spectrometry (ES-MS) on a LCQ
Advantage Max mass spectrometer (Thermo Fisher Scientific, Waltham, MA).
Aza-peptides were synthesized following the same methodology with the
exception of aza-glycine insertion by chemical synthesis at the desired
substitution points during elongation as described previously (Hart and Beeson
2001). Some of the sequences that were synthesized are represented in table 1.

MHC II Binding Assay
The various MBP Ac1-9 peptides were labeled with fluorescein for use in
MHC II binding studies. Soluble I_Au MHC II protein was isolated from BW5134
cell lysate (National Cell Culture, Minneapolis, MN) and purified by M115
antibody exchange column (Millipore, Billerica, MA). An excess of APL (5 J..IM)
was incubated with the isolated MHC II protein (50-100 J..II) overnight at 37°C.
The unlabeled peptide was then removed by Sephadex G50-SF (Sigma) spin
column (-1 ml) purification.

The complex was then incubated at 37°C and

samples (50 J,JI) were taken at time points determined as the experiment
progressed.

Sample composition was monitored with HPLC (Shimaduzu,

Columbia, MO) on a size exclusion column (Phenomenex, Torrance, CA). The
retention time of the MHC II/peptide complex was different than the labeled free
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peptide which allows for semiquantification of the _dissocialipn. The,.p,eak height
'C.
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for the complex is graphed versus time and· the res(}ltinfJ.'·:~~urve is used to
calculate the disassociation halftime of labeled pepl1deir'Om MHC II.

Serum Degradation Half Life Assay
The unlabeled APLs were tested to determine their resistance to protease
degradation.
published

The serum degradation experiments are a modification of

methods

(Kokko

and

Dix 2002)

utilizing

matrix-assisted

laser

desorption/ionization time of flight (MALDI-TOF) mass spectrometry.

The

peptides were dissolved at 10mM in sterile H2 0 and then 30 IJI was added to 270
IJI of rat serum (Sigma). A degradation resistant peptide composed of D-amino
acids was used as an internal standard and was added to the serum at the same
concentration. The mixture was then incubated at 37°C and 20 IJI samples were
taken at specified time points. The time points vary with the protease resistance
of the peptide and the optimum times were determined during testing. The 20 JJI
sample was added to 80 JJI of a 3:1 methanol:ethanol mixture to precipitate the
proteins from the serum and then spun in a microcentrifuge (Eppendorf,
Westbury, NY) at 12,000 g for 10 minutes.

Supernatant, which contained the

peptide, was then combined with a-cyano-4-hydroxycinnamic acid matrix and
spotted on a gold MALDI plate (Applied Biosciences, Foster City, CA).
samples were spotted in triplicate.

The

The ratio between the internal standard

peptide peak and the test peptide peak was then determined using a VoyagerDE STR Biospectrometry Workstation (Applied Biosciences) by MALDI-TOF MS.
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The ratio was graphed against the sample times. The deg:fadation
half-life was
.
. ...
then determined from the equation obtained from thEi"~atuf~i ":l~g:"of the ratio
\

."

,I

graphed against sample times using Microsoft

•

J ...._

:

".

Excel.(Mictos~ff,
.

,;

Bellevue, WA).

T cell Activation Assay

The T cell activation experiments used the L929 cells that have been
transfected with I_Au MHC II protein as an APC cell line (Tate et al. 1995) to
present antigen to the 172.10 T cell hybridoma (Goverman et al. 1993) that has a
TCR specific for rat MBP Ac1-11 peptide.

IL-2 production by the 172.10 cells

was used as an indication of the degree of stimulation through the TCR in
response to the APL being tested. "Aza-peptides from the binding experiment as
well as unlabeled APLs with and without aza-amino acid substitutions were
tested. Serial dilution of test peptides were added to 3 x 104 APC cells and 6.5 x
104 172.10 cells in 96 well plates (Corning, Corning, NY) and incubated at 37 0 C
for 48 hours. Supernatant samples were then taken and frozen at -80 oC until the
cytokine analysis was performed.

The IL-2 concentration was determined by

sandwich ELISA (BD Bioscience, San Diego, CA) in a 96 well plate format
following standard protocols. The absorbance of the ELISA plates was read with
a Vmax absorbance plate reader (Molecular Devices, Sunnyvale, CA) at 450 nm.
The samples were quantitated by comparing the absorbance readings to a
standard curve prepared with known concentrations of IL-2.
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RESULTS

MHC II/MBP Peptide Binding
""

In order for a CD4+ T cell to respond to

.

an antigen and for activation to
."\

take place, the TCR must interact with anantigen/MHC II molecule complex
present on the surface of an APC (Zhu and Paul 2008). The TCR will interact
with the antigen/MHC molecule even if there is some variation in the antigenic
peptide's sequence allowing for a greater immunological range (Hemmer et al.
1998). Changes to this sequence due to amino acid substitution can increase or
decrease the binding time and vary the resulting response from the T cell. The
APLs were tested for binding to soluble I_Au MHC II to determine if the
modification made maintained the peptide/MHC II interaction in order to
predetermine potential usefulness in a cellular system.

Figure 6A is the

representative time plot MBP Ac1-11 peptide with an alanine substituted at
position 4 (4A) and the MBP Ac1-11 with a tyrosine substituted at position 4 (4Y).
The graph represents the peak height on a HPLC readout of the fluorescein
labeled peptides after incubating at 37°C. The formula of the best fit logarithmic
curve of these graphs was used to calculate the dissociation half off time. Figure
6B is a bar graph of the calculated dissociation half times from I_Au MHC II
molecule of the various labeled APLs.
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Figure 6: The Half Off Time of Modified MBP from the I_Au Soluble MHC II
Protein. A, The peak height of the APL/MHC II complex as measured by
integration following HPLC size exclusion at various time points. The inset is the
same data over a shorter time period. B, The calculated half off times of several
aza-APLs compared to the native MBP Ac 1-9 (4K) peptide from the I_AU soluble
MHC II protein. The half off time in minutes is indicated above the bar.
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The formulas for the kinetic graphs were used to calculatelqgarithmid half points
_

-

."

which was taken as the dissociation off half times.
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stronger binding with increased half off binding til:n¢s 'ahd some substitutions
•

.J ....~

resulted in shorter binding times that were comparable to the native 4K MBP
Ac1-9 peptide sequence.

The aza-peptide substitutions altered the binding

kinetics but the binding still occurred, resulting in dissociation half off times that
ranged between the native MBP Ac1-9 peptide (4K) (15 minutes) and a known
strong binding (4Y) (3222 minutes) sequence.

APL Degradation in Rat Serum
The degradation times of the peptides in rat serum were determined to
assess if aza-amino acid substitution provided protease resistance.

Rat serum

was utilized because the native MBP sequence is the rat sequence. Figure 7A
demonstrates representative curves obtained by graphing the ratio of an APL to
a resistant internal standard at various time points following incubation in rat
serum as described in the methods.

The formula for the curve is used to

calculate the degradation half-life of the test peptide. Figure 7B is a bar graph of
the calculated half-lives of some of the APLs that were tested in order to
compare the half-lives of the native MBP Ac1-9 peptide to other natural amino
acid APLs as well as to aza-APLs.
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Figure 7: The Degradation Times of Various APLs in Rat Serum. A, the ratio
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incubation in rat serum at 37°C. B, the calculated half-lives of various substituted
APL compared to the native MBP sequence (4K).
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Comparing the natural peptide APLs to the

.native

:;c.sequence, the

substitution of alanine at position 4 did not appreciqblY,.,a,lte'r' the' half-life (60/0
difference).

Alternatively, a phenylalanine substatio'n '(4F) markedly increased

the half-life (48% increase) while a tyrosine substation (4Y) markedly decreased
the half-life (69% decrease) compared to the native lysine (4K) at position 4.
Substitution with aza-glycine at position 2 or 3 produced APLs that had longer
half-lives than the native sequence. These aza-APLs also possessed half-lives
that were longer than their corresponding native peptide APL. In fact, insertion of
an aza-glycine at position 3 resulted in an APL that was completely resistant to
degradation in rat serum. The substitution of aza-glycine at position 5 conversely
results in an APL with a half-life that was less than the native sequence (81%
less) and also less than the native 4Y APL (38% less).

Effect on T cell Activation
T cell activation assays were performed to assess if the changes made to
the

MBP

sequence

preserved

their

potential

bioactivity.

This

assay

demonstrated that modest changes to the MBP native sequence can still activate
T cells through the TCR that recognizes MBP Ac1-11 (table 1). The bioactivity of
these APLs with aza-amino acid substitutions is demonstrated in a cellular,
system by utilizing cytokine production as an end point. Table 1 displays some
relative IL-2 responses for some of the peptides that were tested. Figure 8 is a
bar graph that represents the maximal IL-2 produced by the 172.10 T cell
hybridomas when stimulated with MBP APLs. The minimal concentration of APL
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required to achieve that maximal IL-2 response is listed b'eTow the bar The inset
graph demonstrates that increasing the APL conce~tr~tio~,·,used, for stimulus
results in a corresponding increased production of .IL~?-. The'maximal response
was taken as the point where the IL-2 increase, re,ached a plateau.

Figure 8

demonstrates that none of the aza-substituted APLs produced an IL-2 response
comparable to the native peptide at any of the concentrations tested. In addition,
no detectable IL-2 was produced when the 3azaG4Y APL or the 4Y5azaG APL
were used as the stimulating peptide.
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Figure 8: The Maximal IL-2 Production from 172.10 Cells Following
Stimulation with Various APLs. The APL concentration required to give the
maximal stimulation is below the respective bar. The inset is a plot of IL-2
concentration at various APL concentrations and the concentration of APL that
produces the maximal IL-2 concentration was taken at the point at which the plot
plateaus.
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DISCUSSION
Utilization of aza-peptide substituted· altered P. .

a

:·_IL.............

novel solution to the problem

in vivo hyperse-hsiti)Jify

based drugs through increased protease_

of the peptide

decreasing the required therapeutic dose.
This study demonstrated the possibility of making subtle
sequence while maintaining binding to an MHC II

antigen

. Maintaining the binding to MHC II

les is the

changes that are made to the peptide sequence. If the changes a
longer possible then the peptide will not

that binding is
to

target T

the

ing to

Figure

properly

demonstrates that aza-peptide insertion

MHC II molecule but that bind

is still preserved.

themselves would significantly reduce the binding rational
the APL sequence, such as position four substitutions to
with greatly increased binding.
M

II molecu
binding is
to altered T

These scaffolds can then

present an APL with an aza-glycine substitution.
the only goal of APLs though as variable binding strengths
responses which are difficult to

ifications

and Beeson 2001).

demonstrated previously as an
(Ryan
a

ict based solely on
Modification

method for creation

al. 2004). So no matter what

sequence based on

M

I substitutions

contact points (figure 3) testing

Increased resistance to protease degradation through altering the native
MBP antigenic sequence with aza-amino acids was also~··d/eHn·bnstrated.

The

utilization of APLs and peptides as drugs has -~he -potential side effects of
hypersensitization and allergic reactions (Bielekova' et al.· 2000; Kappos et al.
2000). The previously tested APLs that made it to clinical trials were stopped as
a result of unintended allergic response potentially due to the high concentrations
required. These high concentrations were required due to low bioavailability as
well as inadequate optimization.

There are various modifications to a peptide

sequence which produce protease resistance.

N-terminal acetylation increases

protease resistance compared to an unacetylated terminus (data not shown).
The native sequence of MBP Ao1-9 is n-terminal acetylated so the starting
peptide has a higher protease resistance compared to a peptide sequences with
a non-acetylated N-terminus. The strategy of using aza-peptides will potentially
reduce the concentration required for clinical effectiveness of APLs though even
more increased protease resistance. Aza-peptides are not naturally occurring so
proteases have not had the evolutionary exposure to develop an active site that
can cleave these (peptide) bonds. These aza-peptide substitutions produced a
further decrease of protease degradation (figure 7B) compared to the native (4K)
sequence.
glycine and

The aza-amino acid substitutions that were made were with azaresulted

in increased protease resistance (4A compared to

2azaG4A) and (4F compared to 2azaG4F). Multiple aza-amino acid substitution
or aza-amino acids substitutions beside glycine are possible and may result in
even greater resistance.

Even though the APL binds to MHC II and
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demonstrates increased resistance to degradation,it

is-~~till l>_en~fkial

to test

whether TCR activation is still possible.
Despite the changes that were made to -the peptide, aza-peptide
substitution can result in an APL that

main~ains

bioactivity as measured by the T

cell activation assay. This assay used a T cell reporter that has a TCR specific
for the native peptide sequence, yet T cell activation and IL-2 production was still
possible with an altered sequence.

This demonstrates both the degenerative

nature of the 172.10 TCR as well as the feasibility of using aza-peptides for APL
creation.

None of the aza-peptide substituted APLs (figure 8) were able to

induce a maximal IL-2 production comparable to the native peptide sequence
(4K) or to certain known strong agonist peptides, such as a 4A substitution,
(table1).

IL-2 production was still possible though and at APL concentrations

(figure 8) comparable to the concentration required for the native peptide to
achieve maximal stimulation. This may mean that the APLs are still effective T
cell antigens and do not require higher concentrations to produce a biologically
relevant effect even though the sequence differs from the native antigenic
peptide.

Further testing would be required in an animal system, after more

thorough optimization of the sequence, in order to confirm the bioactivity of the
effects observed in these experiments.
Aza-peptide inclusion in APLs is a viable technique for the creation of
immune modulatory peptides that display properties of the native sequence yet
possess increased resistance to protease cleavage.

The utility of these aza-

APLs potentially apply to any in vivo situation where peptide based therapies are
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relevant and provides a potential strategy for decreasing the:'hypers¢ositivity side
effects that have, to this point, plagued many of the c1inica1"tr1a,ls~~n(tapplications
as therapeutic treatments.
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CHAPTER THREE

THE INVOLVEMENT OF CALPAIN IN THE
PROCESS OF JURKAT T CELL CHEMOTAXIS

INTRODUCTION
....

-"

T cell involvement in the disease process of MS(Hic.k~Y:f991; McFarland
I

and Martin 2007) and its animal model, EAE ar€. w;eJl''''established (Swanborg
<

2001 a; Waksman and Adams 1962).

•

J\r...

T :cell infiltration of the CNS is greatly

increased in the plaques of MS patients (Hickey 1991) and in the CNS of EAE
animals immediately before the onset of pathological signs and during clinical
disease (Waksman and Adams 1962). Increased activity and expression of the
Ca 2+ -activated protease calpain has been demonstrated in inflammatory cells
(Shields et al. 1999a; Shields et al. 1998) during the disease state in EAE
animals. Moreover, inhibition of calpain has been demonstrated to decrease the
T cell infiltration during acute EAEi ~ (Hassen et al. 2006).

Calpain has known

signaling functions and is involved in a multitude of cellular processes including
apoptosis (Zhivotovsky et al. 1997), activation (Penna et al. 1999; Schaecher et
al. 2004), cell cycle (Janossy et al. 2004) and migration (Franco and
Huttenlocher 2005; Huttenlocher et al. 1997).
T cell exclusion from the CNS is the strategy employed by the FDA
approved a4J31-integrin blocking monoclonal antibody natalizumab (Ransohoff
2007). This drug has not been without problems including several patients on
the medication developing PML (Koralnik 2006a) leading to the temporary
withdrawal of the drug from the market.

In addition, alternative targets for MS

therapy are warranted due to the low effectiveness of many of the current
standard therapies (Kleinschnitz et al. 2007). Targeted exclusion of T cells from
the CNS would be of great benefit not only to MS but for many other autoimmune
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diseases that have a T cell component of their pathology inclueihg .rheumatoid
arthritis (RA) (Cope et al. 2007) and amyotrophic laterats'cterdSis (ALS) (Graves
et al. 2004).

Inflammatory cells entering the CN$- in

MS

and EAE have been

show to have elevated calpain levels (ShieJds e1' al. t998).lf calpain was indeed
involved with T cell migration then calpain in,hibition may provide an alternative
method for reducing pathological T cell entry into the CNS.
Calpain has been shown to be involved in the migration of numerous cell
types including CHO cells (Huttenlocher et al. 1997), fibroblasts (Shiraha et al.
2002), myoblasts (Leloup et al. 2006), and neutrophils (Lokuta et al. 2003). The
chemokine CCL2 (previously known as monocyte chemoattractant protein-1) and
its predominant receptor CCR2" a G protein-coupled receptor, have been
extensively associated with inflammatory pathologies (Jee et al. 2002; Mahad et
al. 2006). CCL2 has been extensively shown as a specific chemoattractant for
monocytes and T cells (Carret al. 1994; Sanders et al. 2000). Even though the
initiating stimulus for migration is well established, the downstream mechanism of
T cell chemotaxis is as of yet incomplete.
In this study, our aim was to gather evidence for the involvement of
calpain in the process of T cell migration. This analysis utilized the Jurkat E6-1
cell line as a model for T cells as well as normal human PBMCs.

Increased

activity of calpain was observed in response to the CCL2 stimulation as well as
the restriction of calpain's role to involvement in the directed migration of
chemotaxis.

This is in contrast to other immune cell types where calpain has

been demonstrated to play a role in the negative regulation of chemokinesis
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(Lokuta et al. 2003).

The current study provides

involvement of calpain in T cell chemotaxis.

prelimTrfary~,evtdehce

for the

Further "exClm,iriation. of calpain's

involvement in the chemotaxis of native T cells and'PJ~lthOlogical T cells from MS
patients and EAE animals is supported by the fin"dings of this study.
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MATERIALS AND METHODS
Cell Culture and Reagents
The T cell type used was the Jurkat E6-1~'''Jir:-ra'(ATCC, Manassas, VA)
grown in RPMI 1640 (MediaTech, Inc., He.rr;dori, VA) media supplemented with
L-glutamine, 100 U/ml penicillin and 1 IJg/ml

~treptomycin

(Gibco, Grand Island,

NY) and 10% FCS (Hyclone, Logan, UT) at 37°C in a 50/0 CO 2 atmosphere

(Thermo Fisher Scientific, Waltham, MA) to desired confluency for each of the
assays performed.

This cell type was selected due to the ease of use and

quantities available.

Fura-2 (Invitrogen, Molecular Probes, Carlsbad, CA) was

used as the calcium indicator dye for the intracellular free calcium assays.
Calcein AM (Invitrogen) was used In the migration assay as the cellular tracking
dye.

Calpeptin (Calbiochem, San Diego, CA) was used as the pan-calpain

inhibitor and CCL2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was the
chemokine used as the chemoattractant in the migration assays. Cytochalasin D
(Sigma, St. Louis, MO) was also used in the migration assay. CMAC, t-80CLeu-Met A6520 (Invitrogen) was used in the calpain activity assay as the
fluorescent calpain specific substrate.

Intracellular Free Calcium Assay
The level of intracellular free [Ca 2+] was measured in Jurkat cells using the
ratiometric fluorescent calcium indicator fura-2 according to our described
method (Das et al. 2005) with slight modification for cell type. Restated is the
modified method for intracellular free [Ca 2+] determination (Grynkiewicz et al.
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1985).

Briefly, cells were grown to 5-6 x 105 cell~/ml iff supp,Ieflj1~nted RPMI

1640, pelleted by centrifugation, washed once with phospha1e· buffered saline
(PBS) and resuspended in 1-2 ml Locke's Buffer (15.4.I1lM NaCI, 5.6 mM KCI, 3.4
mM NaHC03 , 1.2 mM MgCb, 5 mM HEP~S, 1 'mM'CaCI2and 5.6 mM glucose
adjusted to pH 7.4).

The cells were then counted on a hemocytometer and

Locke's Buffer was added to adjust the concentration to 0.5 - 1 x 106 cells/ml for
dye loading. Fura-2 AM was dissolved in DMSO and diluted in the cells to a final
loading concentration of 5 IJM. The cells were loaded with the dye at 37°C for 30
minutes with shaking and protected from light. The cells were then washed 2
times with ice cold Locke's Buffer without Ca2+ and diluted with 4°C Locke's
Buffer to a final concentration of 0:5 x 106 cells/ml and stored on ice until the
assay was performed but no longer than 1 hour. Assays were performed on 1 x
105 cells in 180 IJI in a 96 well plate format using a Gemini XPS fluorescent plate
reader (Molecular Devices, Sunnyvale, CA) and fluorescence was read using
dual excitation and a fixed emission at ex. 340 nm I 380 nm and em. 510 nm.
The plate was loaded with the appropriate number of cells and then incubated at
37°C for 10 minutes to stabilize the temperature then a basal 2 minute kinetic
reading was taken. The experimental test compound was then added to the cells
in 20 }JI and 5 minute kinetic reading was taken.

The fluorescence at the

maximum free [Ca 2+] was then determined by adding 25 IJI of 250 IJM digitonin
(Fisher Scientific, Pittsburg, PA). The fluorescence at the minimum free [Ca2+]
was then determined by the addition 25 IJI of 50 mM EGTA (Sigma).

The

intracellular free [Ca 2+] was calculated from these fluorescence values using the
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equation: [Ca 2+] = ~ (R-Rmin)/(Rmax-R) x (F 380max/F380min)

-Tne cell -Spi9cific value
-

, .

of Kd was determined experimentally to be 1-27 nM for':Jurl<ar'celis by using the
Calcium Calibration Buffer Concentrate Kit (Invitro~ter:t) . . 'The value R is the ratio
of fluorescence emission from the two excitation" waVelengths following exposure
to the test compound. The values Rmax and Rmin are the ratio of fluorescence
emissions following exposure to digitonin and EGTA respectively.

The value

F380max is the resultant fluorescence emission that was measured by excitation at
380 nm when the free [Ca 2+] was zero and was obtained during the EGTA
exposure.

The value F380min is the resultant fluorescence emission that was

measured by excitation at 380 nm for saturating levels of free [Ca 2+] and was
obtained during the digitonin exposure.

Migration Assay
The migration assay was performed with a 96 well format Boyden
Chamber (Neuroprobe, Gaithersburg, MD) following the described methods
(Frevert et al. 1998) with modification for the Jurkat cell type and chemoattractant
optimization.

Specifically, Jurkat cells were grown to confluency as described

above to a final concentration of 1 x 106 cells/ml.

Cells were pelleted by

centrifugation and resuspended in RPMI 1640 without phenol red (MediaTech,
Inc.) supplemented with 0.1 % bovine serum albumin (BSA) (Fisher Scientific).
Calcein AM was dissolved in DMSO and added to the cells at a final
concentration of 2 J.JM and incubated at 37°C for 45 minutes with shaking. The
cells were then washed 2 times with 37°C RMPI 1640 without phenol red and
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resuspended at a concentration of 4 x 106 cells/ml in prepayation fQL~oading the
chamber.

<,

\

The chemokine, CCL2, was diluted to experjm.,ehtally. determined

optimal concentration in RPMI 1640 without phenot',r~'dand added to a 30 J..II 96
well plate (Neuroprobe). A

polycarbonat~filter

witPl 5 J..Im pores (Neuroprobe)

was then attached to the plate. The migration chamber was then assembled and
cells in 50 J..II were added to the top well. The top well volume was then filled with
150 J..II of media or media containing an appropriate test compound. The whole
chamber was incubated for 3 hours protected from light in a 37°C humidified
incubator with 5% C02 atmosphere. The chamber was then disassembled and
the filter was gently scraped with a cell scraper (Fisher Scientific) and washed
with PBS to remove any attached .cells. The plate, with the filter still attached,
was then centrifuged at 400 x g for 10 minutes (Eppendorf, Westbury, NY). The
filter was then carefully detached and the plate read on the fluorescent plate
reader at excitation 485 nm and emission 535 nm.

Calpain Activity Assay
The intracellular calpain activity was assessed following the method
published

by (Shao et al.

instrumentation.

2006) with

modification for cell type and

Briefly, Jurkat cells were grown to desired confluency as

described before and then washed into RPMI 1640 without phenol red and 0.1 %
BSA. The cells were placed in 35mm culture plates (MatTek Corp., Ashland,
MA) with incorporated cover slip for live cell microscopic imaging and kept at
37°C until labeling.

The plates were then placed into a temperature and
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atmospherically controlled stage of a Zeiss LSM 510""'I'JLO .-!aset scanning
confocal/multiphoton microscope (Zeiss, Thornwood i ...~y~ _.-.,equlpped with a
",I.

Coherent Chameleon tunable femtosecond Ti-Sapphire -laser (Coherent, Inc.,
Santa Clara, CA) with META spectral detection (zeiss).

The instrument was

focused before labeling was performed. The amino acid conjugated coumarin
based fluorescent dye CMAC, t-BOC-Leu-Met was then injected into the dish at a
final concentration of 50 IJM. Time lapse microscopic images were then captured
every 15 seconds for 20 minutes.

Various treatments including addition of

chemoattractant and calpain inhibitor were added and then further time lapse
captures were performed. Average spot density from cells in the field were then
averaged and plotted against time to determine increasing fluorescence levels
over time (dF/dt).

Statistical Analysis

All data are shown as means ± SEM. Data from various experiments was
analyzed using SPSS software (SPSS, Inc., Chicago, IL). Statistical significance
was determined by using either the unpaired Student's t test or one way ANOVA
with Games- Howell post hoc test at a 95% confidence interval when multiple
group comparisons were required. Statistical significance was obtained when p
was

s 0.05.

64

RESULTS
-

Intracellular Free [Ca 2+] Level in Response to Chemo~lne and Calpain
Inhibitor

To investigate if an environment tha.t was favbrable for calpain activation
was present in the Jurkat cells during exposure to chemoattractant the
intracellular free calcium concentrations were explored. It has been reported that
certain calpain inhibitors can block the elevation of intracellular free [Ca 2+] levels
(Liu et al. 2002) and this effect was also examined. The Jurkat cells were first
exposed to various extracellular calcium concentrations to determine the effects
on intracellular free [Ca 2 +] levels (figure 9A). Intracellular free [Ca 2+] increased
corresponding to the concentration .dependent increase in the extracellular [Ca 2+]
levels. In order to confirm that our method for measuring intracellular free [Ca 2+]
would measure calcium spikes, indicative of extracellular calcium signaling, 1 IJM
of ionomycin was added to the assay with and without 1 mM extracellular [Ca 2+]
(figure 98). This positive control demonstrated a large calcium spike in contrast
to the low level steady state elevation. The chemokine CCL2 was observed to
elevate intracellular [Ca 2 +] levels when exposed to concentration of 1 ng/ml to
100 ng/ml (figure 9C).

When the cells were exposed to sub ng/ml levels of

CCL2, 0.01 ng/ml, the change in intracellular free [Ca 2+] level was no longer
observed (data not shown). An intracellular free [Ca 2+] elevation in the Jurkat
cells was also observed when exposed to various concentrations (100 nM to 100
IJM) of the calpain inhibitor calpeptin (figure 9D).
increased

The observed trend was

levels of intracellular free [Ca 2+] corresponding to increased
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concentration of calpeptin.

Elevation of intracellular- ft~~ ~lGa~+]; was also

observed in response to various concentrations (10 nM·ilo.. '·1JlM)

of the

calpain

inhibitor P150606 (figure 9E), which binds to the cafciuhl oindirig site of calpain to
prevent activation.
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Figure 9: Intracellular Free [Ca 2+] in Response to Various Ionic Stimulus,
Chemokine Exposure, and Protease Inhibition. Intracellular free [Ca 2+]
changes were measured using the ratiometric intracellular fluorescent dye fura-2
loaded into Jurkat E6-1 cells and read on a fluorescent plate reader following
exposure to experimental compounds. A: Intracellular free [Ca 2+] rise to a steady
state in response to elevated extracellular [Ca 2+]. B: A calcium ionophore,
ionomycin, effectively transports Ca 2+ across the plasma membrane and creates
an intracellular free [Ca 2+] spike in the cell. C: The chemokine CCL2 causes an
elevation in intracellular free [Ca 2+] at an optimum concentration of 10 ng/mL. D:
The calpain inhibitor, calpeptin, causes an elevation of intracellular free [Ca 2+] in
a concentration dependent trend. E: The calpain inhibitor, PD150606, causes an
elevation of intracellular free [Ca 2 +] in a concentration dependent trend. Each
time point represents the mean ± SEM (n = 6-a/time point).
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CCL2 Induced Jurkat Cell Migration is Largely Chemotj"'ctlc

Cellular migration can be divided into increased ra,t1com' motion and
increased directed motion.

Chemokinesis is the"jncrease in random motion

caused by a cytokine, while chemotaxis is:directed motion toward a chemokine.
A standard method (Colvin et al. 2004; Frevert et al. 1998; Wilkinson 1998) of
measuring cellular migration is through the use of a Boyden chamber which is
composed of two compartments separated by a membrane with holes smaller
than the resting diameter of the cell.

In order for cells to move to the lower

compartment and be detected by the assay, they must actively change their
shape and migrate through a pore in the membrane. Jurkat cells placed into a
Boyden chamber will eventually equilibrate over time as random migration of the
cells carry them through the filter membrane (figure 10A) which over the 3 hours
of the experiment appears as migration for the unstimulated group. The effects
of various types of chemokine stimulus can be assessed by where in the
chamber compartments the compounds are placed relative to the cells. CCL2
stimulation in both a chemokinetic fashion, chemokine above and below the filter,
and in a chemotactic manner, chemokine below the filter, produced significant
migration (p < 0.05) compared to the unstimulated group. The major difference
that was observed in the chemotaxis stimulated group (p < 0.05) was significantly
different than both the unstimulated (58%
stimulated (44%

different) groups.

different) and chemokinetically

Increased chemotaxis was observed as a

concentration dependent response (figure 10A) toward higher concentrations of
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CCL2 until the cells reached maximal chemotaxis· ·1:11'50.- ngjml CCL2.
Concentrations of CCL2 above 50 ng/ml did not increase Gh~.ot~xis.

Calpain Inhibition is Restricted to Rectucing Chemotaxis in Jurkat Cells
Stimulated with CCL2
Previous work on other immune cell types have reported that calpain is a
negative regulator of cell migration and that calpain inhibition leads to increased
chemokinesis (Lokuta et al. 2003). In order to determine if calpain plays a similar
negative regulator role for chemokinesis in Jurkat T cells migration assays were
performed with a calpeptin gradient without chemokine stimulation (figure 108).
In this unstimulated environment (no CCL2 present) cellular migration was not
significantly different than control (no calpeptin) for any of the calpeptin
concentrations tested. Jurkat T cells migration assays were also performed with
chemokine stimulation in a chemokinetic environment (figure 1~C).

In this

chemokinetically stimulated environment, CCL2 (50 ng/ml) above and below the
membrane, cellular migration was also not significantly different than control (no
calpeptin) for any of the calpeptin concentrations tested.

In contrast, calpain

inhibition did produce a significant (p < 0.05) concentration dependent reduction
in chemotaxis toward CCL2 (50 ng/ml) (figure 100). Chemotaxis was reduced by
31.1%, 39.5%, and 68.1 % at 1 ~M, 10 IJM and 100 IJM of calpeptin respectively.
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Figure 10: Effect of Calpain Inhibitor, Calpeptin, on CCL2-lnduced
Chemokinesis and Chemotaxis in Jurkat E6-1 Cells. Jurkat cells were loaded
with the fluorescent dye calcein AM to aid in cell tracking and then loaded into a
96 well Boyden Chamber with various treatments to assess migration status. A:
CCL2 (50 ng/ml) was placed both above and below the chamber's filter
membrane to study the chemokinetic response or was only placed below the
filter to study the chemotactic response. Mean ± SEM (n = 8). *, P < 0.05 vs
unstimulated; t, p < 0.05 vs chemokinesis. B: Calpain inhibition with calpeptin in
the absence of CCL2 did not significantly alter the levels of migration at any of
the concentrations tested. C: Inhibition of calpain with calpeptin did not
significantly alter the migration of Jurkat cells in response to a chemokinetic
stimulation (50 ng/ml CCL2 above and below the filter membrane). D: Calpeptin
caused a concentration dependent inhibition of migration of cells toward CCL2
(50 ng/ml). Mean ± SEM (n = 8). *, P < 0.05 vs vehicle (Set as 100%
chemotaxis).
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Calpain Inhibition also Reduces Chemotaxis in Humay,:-'P"aM,C"$ .Stimulated
with CCL2
Migration assays were also performed on. normal human PBMCs In
response to chemotactic stimulation by GCL2' in ~he presence of the calpain
inhibitor calpeptin.

Calpain inhibition produced a significant (p < 0.05)

concentration dependent reduction in chemotaxis toward CCL2 (100 ng/ml)
(figure 11). Chemotaxis was reduced by 19.4%, 42.1 %, and 41.70/0 at 1 f.,JM, 10
tJM and 100 JJM of calpeptin respectively.

Chemotaxis also trended toward

reduced migration with the two lower concentrations of calpeptin of 10 nM and
100 nM.
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Figure 11: Effect of Calpain Inhibitor, Calpeptin, on CCL2-lnduced
Chemotaxis in Human PBMC Cells. PBMCs were loaded with the fluorescent
dye calcein AM to aid in cell tracking and then loaded into a 96 well Boyden
Chamber with various treatments to assess migration status. Calpeptin caused a
concentration dependent inhibition of migration of cells toward CCL2 (100 ng/ml).
Mean ± SEM (n =3). *, p < 0.05 vs control (Set as 100 % chemotaxis).
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Calpain is Part of a Chemotaxis Signaling Cascade
The number of cells that undergo. chemotaxis toWa:fd .a signal is
dependent upon the concentration of that signal. /,}he. . optimal concentration of
CCL2 to induce maximal chemotaxis '!Vas aetetmined by performing the
migration assay with a chemoattractant gradient (figure 12A). The highest level
of chemotaxis was observed at 50 ng/ml of CCL2 even though the chemotactic
effect appeared to plateau at concentrations greater the 50 ng/ml.

Calpain

inhibition with calpeptin at the experimentally derived IDso for Jurkat cell
chemotaxis toward CCL2 (50 lJM) produced a significant inhibition of chemotaxis
(p < 0.05) for all of the CCL2 concentrations tested compared to chemotaxis
without calpain inhibition (figure 12A). At the lower concentrations of CCL2 (1
ng/ml - 50 ng/ml) there was significant inhibition (p < 0.05) of chemotaxis with
calpeptin compared to control levels. This significance disappeared at the higher
concentrations of CCL2 (100 ng/ml and 500 ng/ml). The polymerization of actin
is a non-signaling mechanism that is required for migration to occur (VicenteManzanares et al. 2005). Inhibition of this process with cytochalasin D (25 lJM)
produced a significant inhibition (p < 0.05) of chemotaxis at CCL2 concentrations
of 10ng/ml through 500 ng/ml (figure 128). The percentages of chemotaxis in
the cytochalasin D groups compared to control were not significantly different at
any of the concentration of CCL2 tested. Cytochalasin D (25lJM) and calpeptin
(50 lJM) were also tested together in order to determine if the migratory inhibition
effect was additive by using both compounds (figure 12C).

Inhibition of this

process with cytochalasin D (25 lJM) and calpeptin (50 lJM) produced a
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significant inhibition (p < 0.05) of chemotaxis at CCL2 conc~'ntrat101)s)of 10ng/ml
through 500 ng/ml compared to the media only group:i~ ·S~gnnTcant difference
between the cytochalasin D group (figure 128) ~q . .t~e combined treatment
group (figure 12C) was not observed though the combined group trends toward
less chemotaxis.
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Figure 12: Effect of Chemoattractant Concentration on Calpain InhibitorInduced Reduction in Chemotaxis: A Response Distinct from the Inhibition
by Cytochalasin D. Chemoattractant was loaded in the lower wells of a 96 well
Boyden chamber in increasing concentrations while Jurkat cells were loaded in
the upper chamber. A: The chemotaxis of Jurkat cells in the increasing
chemoattractant gradient is compared to chemotaxis in the same gradient when
an IC so concentration of calpeptin was added to the cells in the upper wells.
Chemotaxis of Jurkat cells was highest at an optimum CCL2 concentration of 50
ng/ml. Calpeptin-induced reduction in chemotaxis was observed only up to 50
ng/mL of CCL2 and the effect was lost at higher CCL2 concentration. Mean ±
SEM (n = 8). *, P < 0.05 between groups for media in upper chamber vs calpain
inhibitor; t, p < 0.05 migration inhibition compared to control. B: The chemotaxis
of Jurkat cells in the increasing chemoattractant gradient is compared to
chemotaxis in the same gradient when the actin polymerization inhibitor,
cytochalasin D was added to the cells in the upper wells. Cytochalasin D groups
were not significantly different than control, however it could significantly
attenuate the CCL2 induced chemotaxis. Mean ± SEM (n = 8). *, P < 0.05
between groups for media in upper chamber vs cytochalasin D. C: The
chemotaxis of Jurkat cells in the increasing chemoattractant gradient is
compared to chemotaxis in the same gradient when cytochalasin 0 and calpeptin
was added to the upper wells. Combined treatment group displayed the same
trend as cytochalasin D treatment alone. Mean ± SEM (n
4). *, P < 0.05
between groups for media in upper chamber vs calpeptin and cytochalasin D.
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Direct Observation of Calpain Activity in Response toCCL~ExPQsure

The effect of calpain on chemotaxis has beeniAdireCflY" irlferred in the
previous experiments from effects observed with a bjocbe'-rnicar inhibitor. In order
to directly assess if calpain activity increa,s.ed in response to CCL2 stimulation
live cell imaging of a fluorescent dye coupled to a calpain substrate was used.
The specificity of CMAC, t-80C-Leu-Met as a calpain substrate and thereby
indicator of calpain activity has been previously shown (Shao et al. 2006) in
hepatocytes.

Jurkat E6-1 cells used in this study displayed a basal level of

calpain activity (figure 13A-D) so the protocol was modified accordingly for this
cell type.

Due to this basal activity simple fluorescence compared to non-

fluorescence would not indicate altered activity. Sample micrographs from three
groups of time lapse series (figure 13A) demonstrated the basal level of activity
with increased fluorescence over time as well as increased fluorescent over time
in the CCL2 (50 ng/ml) group. The CCL2 (50 ng/ml) + calpeptin (100 IJM) series
demonstrated the specificity of CMAC, t-80C-Leu-Met as a calpain substrate.
The masking examples (figure 138) demonstrated the importance of choosing
cells at random from the field of view due to the differential response in the
culture between strong responders and weak responders. The same mask was
used at each time point to track the same cells for the entire time of the
experiment. The average spot density of the representative cells (10 for each
field) were graphed against time for each of the exposures (figure 13C) revealing
the differential response. 80th the basal and the CCL2 groups revealed calpain
activity while the CCL2 + calpeptin group did not show any activity. This data
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was quantified by comparing the rate of increasing fluores~~.nce (pr./dt) (figure
13D). The CCL2 stimulated group demonstrated a dF/cit that\lttas significantly
higher (p < 0.05) than the unstimulated basal group.~ ~the 'CCL2 + calpeptin
group had a dF/dt significantly lower (p < 0;05) ttian both the basal and the CCL2
stimulated groups.

77

B

A

. . .....

..

Basal
~

o

I

0
~ sooo

100

200

300

100

200

300

Q.)

'0
(5 10000
Q.

en

CCL2

Q)

Ol

1!
Q)

ct

oI
0

CCL2
+
Calpeptin

Smin

15 min

Masking Example

o ~~~~.t!!~i~'!:l'

I
' L

o

100

700

300

Time (Sec)

D

*

20

15

~
u.. 10
"'0

*

5

.1.

0

Basa l

CCL2

CCL2
+
Calpeptin

Figure 13: Intracellular Calpain Activity Increased in Response to the
Chemokine CCL2. Increased calpain activity was imaged in live Jurkat E6-1
cells based on the increasing fluorescence of the calpain specific dye CMAC, tBOC-Leu-Met following exposure to chemokine (50 ng/ml CCL2) or calpain
inhibitor (100 fJM calpeptin). A: Representative micrographs from a 15-min time
lapse exposure measuring fluorescence of 50 fJM CMAC at 370 nm. B:
Representative images of spot density selections of random cells which was
repeated for every time point. C: The average spot density of ten individual cells
over the time lapse series for each exposure group. The mean of the ten cells is
also included on each of the graphs. D: The change in average fluorescence
density for the mean of each experimental group. Mean ± SEM (n = 10). *, P <
0.05 between the experimental groups and basal dF/dt; t, p < 0.05 between the
CCL2 group and CCL2 + Calpeptin group.
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DISCUSSION

Migration of the adaptive immune system's

ceUula(.~·-components

into

pathological areas in response to chemokine signalf!1g"i$' 'important for organisms
to fight infection. The existence of autoimmune disease is evidence that this vital
immune response does not always function. in a way that is beneficial to the
organism as a whole. T cell migration into areas of inflammation is a critical step
in their role in the pathology of the autoimmune conditions in which they
participate. T cell infiltration into the CNS of MS patients and EAE animals has a
strong correlation with the disease pathology observed.

The infiltrating

inflammatory cells and T cells have been shown to have increased calpain
expression and activity (Shields et al. 1998). Even more important, treatment
with calpain inhibitor has the ability to reduce the clinical score in EAE and also
improve the morphology of the CNS tissue (Guyton et al. 2006; Hassen et al.
2006).
Calpain has been shown to have a role in the migration of various cell
types but, as of yet, never in the adaptive immune cell type of T cells. Evidence
for calpain's direct involvement in chemotaxis toward CCL2 was presented in
these experiments and its differing role in cellular migration from the innate
immune cell type of neutrophils (Lokuta et al. 2003).

The intracellular

environment in response to CCL2 was demonstrated as supportive for calpain
activation (figure 9C). Other work (Bach et al. 2007) has also demonstrated an
intracellular calcium elevation in response to the chemokine CXCL 12 (SDF-1a)
which provides evidence for the involvement of calpain in the chemotactic
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response to various chemokines and is not limited ,to ~\CCl.:2~

Whenever

intracellular calcium levels change to another ·steady statei cal.j:fcHfl activity should
be investigated. Our use of calpeptin also appearg; to .cause
steady state intracellular free calcium levels (figure 9D).

a mild elevation in

Previous work has

demonstrated that certain calpain inhibitors. have the ability to block further
calcium uptake (Liu et al. 2002). Calpeptin is of a class of protease inhibitors that
binds to the active site of calpain and not to the calcium binding site (Ray et al.
2003a; Wang 1990). This means that irrespective of the resulting intracellular
calcium level in response to calpeptin treatment, calpain activity will still be
inhibited. The intracellular free calcium levels were also measured in response
to the calpain inhibitor PD150606 which inhibits calpain by binding to the calcium
binding site (Wang et al. 1996) to prevent protease activation and a similar mild
elevation of intracellular calcium levels was also observed (figure 9E). This mild
elevation could be an inherent property of all calpain inhibitors due to
homeostatic feedback control of basal calpain activity on intracellular free [Ca 2+]
but it is small enough to go undetected in most studies and is not large enough to
alter the calpain inhibition.
Our current work supports that of previous work with CCL2 in that it
functions on T cells primarily as a chemotactic cytokine and has limited
chemokinetic properties (Carr et al. 1994). Calpain inhibition appears directly
concentration dependent with respect to chemotaxis reduction, in that the greater
the inhibition the greater the reduction in chemotaxis. Our current work differs
from previous reports (Lokuta et al. 2003) in that the demonstration of a
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significant role for calpain in the process of chemokinesis \A/a,S~ not ;obssible but
our results were primarily restricted to chemotaxis (figure·" to).

There are a

number of possible reasons for this discrepancy Ihc.tudlng differing cell types,
sensitivity of assays used, various migratory stimulation utilized and various
calpain inhibitors used. While the difference is note worthy between previous
studies, the disease relevance is more important for directed migration which
would guide pathogenic T cells to the CNS in EAE and MS. The observation of
this inhibitory effect in Jurkat T cells (figure 10D) as well as in normal human
PBMCs (figure 11) adds increased evidence to its relevance as a disease
relevant process. The exact role of calpain in chemokine induced chemotaxis is
as of yet unknown, but evidence

po~nts

to its involvement in a signaling pathway.

The ability of an increasing concentration of CCL2 to overcome calpeptin induced
chemotactic inhibition (figure 12A) lends evidence to a role in a signaling
pathway. When a known downstream effect, polymerization of actin, of migration
is blocked with a pharmacological agent, cytochalasin D, the inhibition and
recovery effect observed with the calpain inhibitor is not reproduced, further
strengthening the evidence for the specific involvement of a calpain-mediated
mechanism in T cell chemotaxis.

Chemotaxis was also examined with a

combined treatment of calpeptin and cytochalasin D to determine if the
compounds produced an additive effect. The combined treatment (figure 12C)
produced a profile similar to cytochalasin D alone (figure 128) but with a nonsignificant trend toward slightly greater inhibition. This profile provides further
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evidence that the cytochalasin D acts downstream of calpai.n. in ih~ migration
mechanism as the cytochalasin D profile alone (figure 128.)- is f~ptoduced.
The current work has been performed on ;'JLJtkat :-E6-'1 cells to provide
preliminary data in a T cell like cell before,'expansion into cells directly obtained
from and derived from MS patients andEAE animals.

In order to add more

relevance to this work as a transition to work in more disease relevant models a
similar observed effect in normal human PBMC was presented (figure 11). While
the current work does not provide direct evidence for therapeutic intervention it
does support the continued expansion into more disease relevant models. The
current study also does not address the specific isoforms of calpain that may be
involved with migration.

The two ,major ubiquitous calpains IJ-calpain and rn-

calpain are often expressed at different levels in various cell types which may
also be the case of the Jurkat cells. The current study identifies a basal level of
calpain activity (figure 13) and also calpain expression (data not shown). Calpain
changes using western blot were also attempted, which would allow for
identification of subtypes with various specific antibodies.

Unfortunately, the

changes were not large enough to detect differences between treatment groups.
The short time frames in which migration occurs would tend to favor changes in
activity over changes in protein expression. The lack of inhibitors specific for the
subtypes is also a limitation for assessing protease subtype variations. Future
studies are ongoing, with more disease relevant cell types, using RNAi to assess
these more specific changes and narrow down the protease isotypes involved.
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Current MS treatments are moderately effective at best (Kleiflschnitz et al.
2007) and most treatments eventually loose 'effectivene~ for·,:-h1any patients as
the disease progresses.

Therapies that targe)
. R"" "mechanism
selectively
"'
.

upregulated or active during the disease state, such as increased calpain activity
in T cells from MS patients (Imam et al. 2007), provide a targeted approach that
may prove an effective treatment. Calpain activity contributes to many cellular
processes including apoptosis (Zhivotovsky et al. 1997), cell cycle regulation
(Witkowski and Bryl 2004), T cell activation (Schaecher et al. 2001), and T cell
chemotaxis (as shown in this investigation).
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CHAPTER FOUR

THE INVOLVEMENT OF CALPAIN IN
CD4+ T HELPER CELL BIAS

INTRODUCTION

Multiple sclerosis (MS) is an autoimmune disease of the eNS that is
thought in large part to be initiated and mediated by an inflammatory infiltration of
the eNS by self reactive CD4+ T helper cells (McFarland and Martin 2007).
Different autoimmune

diseas~s

depend on the nature of the immune response

and the proliferation of certain Th subtypes. MS is thought to be the result of the
development of an inflammatory Th cell bias composed of overreactive Th1 and
Th17 subtypes leading to a self directed inflammatory attack resulting in myelin
degeneration and the pathological symptoms observed.

T helper cell bias is

controlled through the binding affinity of the antigenic peptide, the associated
molecules present and the prevalent cytokine environment (Zhu and Paul 2008).
The T cell differentiates through specific signaling pathways, including various
STAT molecule subtypes which transmit the activation response to certain
transcription factors upregulating specific cytokine loci and reinforce the T helper
cell subtype.

There is cross reactivity in the signaling pathways but taking a

simplistic view Th1 subtype develops from IFN-y and IL-12 signal through
STAT1fT-bet to drive further cytokine expression and subtype reinforcement.
Th2 subtype develops from IL-4 and IL-2 signaling through STAT6/GATA3. Th17
subtype develops through TGFr3, IL-1 and IL-6, IL-21, IL-23 signaling through
STAT3/RORyt to develop and reinforce the subtype. Finally, the Treg subtype
develops through

TGF~

and IL-2 signaling though STATS/Foxp3 to drive further

regulatory cytokine secretion (Zhu and Paul 2008). This is a simplistic overview
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of the signaling but gives a framework in which to identify-someof,thl3 signaling
components on which calpain may be acting ..
Various STAT molecules are known su6s~rate's of the ubiquitously
expressed calcium activated protease, ·calpain rHendry and John 2004).
Previous studies have shown that activated STAT6 is degraded in T cell
hybridoma cells and this degradation can be prevented with calpain inhibitors
(Zamorano et al. 2005). STAT6 which is known to contribute to the Th2 subtype
bias through IL-4 (Zhu et al. 2001). The Th2 subtype also has the ability to down
regulate the Th1 and Th17 type cells through cytokine secretion. Our lab and
others have observed that EAE disease signs are reduced with calpain inhibitor
treatment (Guyton et al. 2006; Hassen et al. 2006). The regulation of STAT6
through activation and its target transcription factors may be a mechanism
through which calpain inhibition provides clinical benefit.
The lab has also demonstrated increased calpain activity in the infiltrating
monocytes during acute EAE which tend to be biased toward the Th1 and Th17
subtypes (Shields et al. 1998). The correlation between calpain activity and T
cell subtype may be circumstantial or may have real merit.

From these

observations, the hypothesis was formed that calpain activity is involved with T
helper cell bias.

This hypothesis was tested by utilizing primary MBP Ac1-11

specific T cell cultures biased toward the various T helper cell subtypes, as well
as several MBP Ac1-11 specific T cell lines to perform proliferation assays,
monitor cytokine profile, and perform western blotting for transcription and
signaling molecules in the presence of various concentrations of several classes
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of calpain inhibitors. These studies provide insight into the variousj~"ies calpain
plays in Th cell bias and proliferation and increases ourlJ'nder$landing of the role
that T cells play in the pathophysiology of EAl: ,'an'o MS as well as the
mechanisms involved by which calpain inhibitors decrease the disease signs of

EAE.
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MATERIALS AND METHODS

MBP Specific T cell Culture
CD4+ T helper cells (810A.E3 or 810A.E2) were originally isolated from
B10.A-H2a H2-T18 a/SgSnJ (Jackson Labs, Bar Harbor, ME) mice peritoneal
lymph nodes (LN) following subcutaneous (s.c.) inoculation with MBP Ac1-11 in
complete Freund's adjuvant (Rabinowitz et al. 1997). The cells were diluted to a
single cell culture

and

stimulated with

v-irradiated

(3000

rad)

isogenic

speloncytes, MBP Ac1-11 and r1L-2 (Invitrogen). The cells were grown in RPMI
1640 (MediaTech, Inc., Herndon, VA) supplemented with 10%

FCS (Hyelone,

Logan, UT), 10 mM HEPES (Sigma), 2 mM GlutaMAX (Invitrogen), and 50 ~M ~
mercaptoethanol (Gibeo, Grand Island, NY). The cells were restimulated every

7-9 days with a 10 fold excess of v-irradiated isogenic speloncytes, 50 JJM MBP
Ac1-11 and r1L-2 and maintained at 6-7 x 105 cells/ml.

Media and r1L-2 was

added during the first 72 hours and cells were split as needed to maintain the
proper cellular concentration. At the time of restimulation the required cells were
split off for assays. The MBP specific cell lines were utilized for the proliferation
assay, cytokine profiling, western blotting, flow cytometry, subcellular localization
microscopy and adoptive transfer of EAE.

Primary MBP Specific T cell Culture
Proliferation assay and cytokine profiling were performed on the various
subtypes of helper T cells using cytokine biased primary culture.

810.PL mice

(Jackson Labs) were injected s.c. with an emulsification of 400 JJ9 of guinea pig
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- MBP in complete Freund's adjuvant (Difco, Lawrence, KS) at four locations over

the back followed with 200

~g

of pertussis toxin (Sigma) injected intraperitoneal

(Lp.) at the time of inoculation and then again 48 hours later. Ten to twelve days
later the draining LNs and the spleen were dissected out and fritted glass slides
were used to grind the tissue into a single cell suspension and strained through a
70 JJm cell filter (BD Biosciences) to remove the larger tissue debris. The LN
cells were grown with a 10 fold excess of spleen cells and were stimulated with
50 tJM MBP Ac1-11 in the same media as the MBP specific cell culture lines.
The

various

subtypes

favored

for

proliferation

with

exogenous

recombinant cytokines and neutralizing antibodies. For Th1 potentiation, IL-12
(10 ng/ml; R&D Systems, Minneapolis, MN) and anti-IL-4 (2 tJ9/ml; R&D Systems
or Santa Cruz Biotechnology, Santa Cruz, CA).

For Th2 potentiation, IL-4 (10

ng/ml; Cell Sciences, Canton, MA) and anti-IL-12 (2

~g/ml;

R&D Systems). For

Th17 potentiation, IL-1J3 and IL-23 (10 ng/ml; R&D Systems) and anti-IFN-y and
anti-IL-4 (1 0

~g/ml;

Biosciences) and

R&D Systems).

TGF~1

For Treg potentiation, IL-2 (150 U/ml; BD

(1 ng/ml; R&D Systems) and anti-IFN-y and anti-IL-4

(10 IJg/ml; R&D Systems). The cytokines were chosen not to differentiate na'ive
T helper cells to the respective subtypes but rather to reinforce the proliferation of
the differentiated subtypes already present in the culture. Supernatant samples
were taken at 24 hours following plating and the media was replaced with fresh
media and comparable cytokines and antibodies.
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Proliferation Assay
The proliferation assay was set up on a restimulation day for the MBP
specific T cell cultures or on the day of plating for the primary culture. The assay

was performed in 96 well plates (Corning) with 8-9 x 104 MBP specific T cells per
well and a 6-10 fold excess of v-irradiated isogenic speloncytes as antigen
presenting cells per well. Cells were activated with either the native MBP Ac1-11
peptide or a MBP Ac1-11 peptide with an alanine substitution at position 4 for a
positive stimulation control.

Various concentrations of calpain inhibitors were

added to the wells. No r1L-2 was used in this assay during the stimulation. The
primary culture had the appropriate cytokines and antibodies added to the media.
After 24 hours 100 J..II of supernatant was removed for cytokine profiling and 2 J.,JCi
of 3H-thymidine in fresh media was added to each well. After 24 more hours the

cells were lifted with trypsin EDTA (Invitrogen) treatment and harvested with a
semi-automated cell harvester (Skatron Instruments, Sterling, VA) onto a filter
paper membrane (Skatron).

Each well's filter was added to a scintillation vial

(Fisher Scientific) with 2 ml of Ecoscint A (National Diagnostics, Atlanta, GA)
scintillation fluid. A TRI-CARB 2900TR Liquid scintillation analyzer (PerkinElmer,
Shelton, CT) was utilized to determine the amount of 3H-thymidine present in the

cells as an indicator of DNA replication and proliferation.

Cytokine Profiling
Cells were grown to desired confluency and either plated in a 96 well plate
for proliferation assay testing or in 6 well plates for large scale experiments. Cell
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free supernatant was collected 24 hours after exposure to the specified
treatments and frozen at -BOoC until the cytokines were assayed.

OptlEA

Sandwich ELISA (BD Biosciences) was utilized to test for individual cytokine
levels in the various exposures following the standard protocol.

A matched

antibody pair (BD Biosciences) was utilized for IL-17A with a modified ELISA
protocol based upon the BD kit instructions. The cytokines tested were IL-2, IFNV, IL-12p70, IL-4, IL-10 and IL-17A. The cytokine profile of the E3 cells and
unbiased primary T cells were further explored using an inflammatory cytokine
antibody array (Ray Biotech Inc, Norcross, GA) to more fully characterize the
subtype profile. This array is an immunoblot array performed following the kit
instructions and detected on a Fluochem FC2 Chemiluminescent CCD detection
system (Alpha Innotech). AphaEaseFC (Alpha Innotech) software was used to
calculate the densitometry of the various spots in the array and Excel (Microsoft)
was used to graph the data.

Western Blotting

Briefly, the total protein samples were extracted following the lysis with
ultrasonic homogenization of control and treated MBP specific T cells,
quantitated spectrophotometrically, denatured in boiling water for 5 min, and
loaded onto 8DS-polyacrylamide gradient (4-20%) gel (Bio-Rad Laboratories,
Hercules, CA). The proteins were resolved by electrophoresis in Laemmli buffer,
and then electroblotted to ImmobilonTM-P membranes (Millipore, Bedford, MA,
USA). For detection of each specific protein band on the blots, appropriate
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dilutions of the primary IgG antibodies were used either 1:250 or 1: 1000
depending on the supplier.

STAT 1, 4 and 6, T-bet and GATA3 primary

antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The
blots were first incubated with the primary IgG antibody followed by incubation
with

the

appropriate

alkaline

horseradish

peroxidase

(HRP)-conjugated

secondary IgG antibody (leN Pharmaceuticals, Aurora, OH). The ChemiGlow
(Alpha Innotech, San Leandro, CA) H2 0 2 catalyzed substrate solution was added
to the blots.

The protein bands were then detected with a Fluochem FC2

Chemiluminescent CCO detection system (Alpha Innotech). The images were
then processed using AphaEaseFC (Alpha Innotech) to quantify the 00 units of
the bands. J3-Actin expression was used as a control for equal loading and to
normalize the samples to one another.

Microscopy

The subcellular localization of transcription factors was visualized utilizing
fluorescent

immunohistochemistry

instrumentation.

with

modification

for

cell

type

and

Briefly, T cells were plated at standard concentration for 48

hours with designated experimental conditions. Cells were then lifted, washed
twice with blocking buffer (8B), PBS with 1% goat serum (Hyclone) and 1010
horse serum (Hyclone), and then fixed with -20°C MeOH for 5 min. Cells were
washed again with BS and then incubated for 40 min with 1:50 primary antibody
at 4°C.

Cells were washed with BB then incubated for 30 min with 1:50

fluorescent secondary antibody at 4°C protected from light. Cells were washed
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again with BB and resuspended in a minimal amount of Vectashield with DAPI

(Vector Labs, Bur\\ngame, CA.) and then mounted \n 35 mm cu\ture p\ates
(MatTek Corp., Ashland, MA) with incorporated cover slip for microscopic
imaging and kept at 4°C until imaging. The plates were imaged with a Zeiss LSM
510 NLO laser scanning confocal/multiphoton microscope (Zeiss, Thornwood,

NY) equipped with a Coherent Chameleon tunable femtosecond Ti-Sapphire
laser (Coherent, Inc., Santa Clara, CA) with META spectral detection (Zeiss).
The various fluorescent channels were imaged simultaneously and digitally
overlaid.

Statistical Analysis
All data are shown at means ± SEM. Data from various experiments was
analyzed using SPSS software (SPSS, Inc., Chicago, IL). Statistical significance
was determined by using either the unpaired Student's t test or one way ANOVA
with Games- Howell post hoc test at a 95% confidence interval when multiple
group comparisons were required. Statistical significance was obtained when p
was < 0.05.
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RESULTS
Calpain Inhibition Increases Th2 Subtype Proliferation
The proliferation of several MBP Ac1-11 specific cell lines with various
concentrations of several APLs was measured to demonstrate the proliferation
potential related to antigenic stimulation. These studies were also performed to
identify the proper stimulation to use for future studies. The APL (4A) , MBP Ac111 with alanine at position 4, binds to MHC II much stronger than the native
peptide (figure 5), produced increased proliferation compared to the proliferation
that results from stimulation with the native antigen (4K). When the proliferation
assay was performed on the E3 cells with various concentrations of the calpain
inhibitor calpeptin
observed.

a concentration dependent proliferative response was

f

Figure 14A compares the 3H-thymidine incorporation across the

various stimulation and treatment groups. A more graded effect is observed with
the native (4K) peptide stimulation.

Figure 14B transforms the 3H-thymidine

incorporation into a percentage relative to each stimulation group's vehicle
control set at 100 %

•

This allows for a more direct comparison of the effect of

calpeptin on proliferation.

Figure 14B demonstrates that the maximum

proliferation of the E3 cells is observed when 10nM of calpeptin is present in the
culture. The proliferation of E3 is significantly greater than both controls when
stimulated with the 4K peptide.

94

0.12

A

- No Peptide
D4K
D4A

U 0.08

,-::;
QJ

c

'1'.J

E

>-

r

~

M

I

0,04

Control

Vehicle 0,2% DMSO

100nM

1nM

10nM

Calpeptin Concentration
800~--------------------------------------------

B

-No peptide
D4K
D4A

QJ

U

..r::.

600~----------------------------~

QJ

>

E
QJ

>

''::;

~

a::
c

400~--------------------~------~

o

''::;

~

~
'0

0:

200+--- - - - - - - - - - - 1

.....0
0 '"

o

Control

Vehicle 0.2% DMSO

100nM

10nM

1nM

Calpeptin Concentration

Figure 14: T Cell Proliferation with Various Stimuli. Proliferation of MBP Ac111 specific T cells either in the presence of no antigenic peptide, the native MBP
Ac1-11 (4K) peptide, or a strong agonist APL MBP Ac1-11 with an alanine
substitution at position 4 (4A). Cells were incubated in the presence of several
concentration of the calpain inhibitor calpeptin.
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From the results obtained in figure 14, the native 4K MBP peptide was
chosen for further studies of the effect of calpain inhibition on proliferation
the graded

Figure 15 shows the results of proliferation experiments

performed with a wider range of concentrations of calpeptin used to determine if
proliferative effect was concentration dependent. The proliferation of

of

the groups except the 100 pM calpeptin group were significantly greater than the
unstimulated group. The groups trended toward increased proliferation at
midrange of calpeptin concentrations tested and returned
independent level of stimulation at the lower concentrations.

the
proliferation

was significantly higher than the stimulated group when 1 IJM of calpeptin was
also present in the culture. The subtype of the cells used for figures 14 and 15
was suspected to

Th2 from cytokines studies present later in this chapter. In

order to determine if the proliferative effect of calpain inhibition was restricted

a

particular Th subtype the next set of experiments repeat the proliferation assays
on the various subtypes of Th cells.
effect of calpain inhibition on the various Th cell subtypes in the
context of cellular proliferation potential was determined.

Cells were

from draining LN and spleen from mice 10 days following MBP inoculation
restimulated with MBP Ac1-8 (4K) as described in the methods to favor
proliferation of

specific CD4+ T helper cell subtypes.

Figure 16

the

thymidine incorporation into these cells when biased toward the various
profiles in the presence of various concentrations of the calpain inhibitor,
calpeptin.

16 gives an overview of all of the various subtypes
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each other.

When the proliferation experiment is performed without biasing

cytokines or antibodies present in the media (figure 17A) there is no significant
effect on proliferation from the various concentrations of calpeptin compared to
unstimulated or stimulated controls. When the cells are cultured in the presence
of the cytokines favoring the proliferation of the Th 1 or Th 17 (figures 17B and
170) subtypes the addition of calpeptin either, does not affect 3H-thymidine
uptake or actually decreases 3H-thymidine uptake meaning that proliferation is
either not affected or is decreased compare to the control cells. When the cells
are cultured to favor Th2 subtype (figure 17C) the addition of calpeptin increases
3H-thymidine uptake--at the middle range of inhibitor concentration.

The

proliferation profile results in figure 17C more closely match the results observed
in figure 15 with the E3 MBP specific cell culture line. The addition of calpeptin
results in significantly increased 3H-thymidine incorporation in the 10 J.,IM, 1 J.,IM,
100

~M

groups compared to the stimulation group without calpain inhibitor. The

proliferation increase peaks at 100 nM of calpeptin and decreases back to the
control level of 3H-thymidine incorporation in a concentration dependent manner.
Figure 18A-C compares the 3H-thymidine levels between the various
subtypes for each group and concentration of calpeptin tested.

Figure 18A

compares Th1 to Th2 and they are significantly different between every calpeptin
group besides the highest two (10 J.,IM and 1 J.,IM). Figure 188 compares Th1 to
Th17. There is significant difference between the subtypes at 10 nM and 1 pM of
calpeptin. Figure 18C compares Th2 subtype to Th17. The proliferation of these

two subtypes is significantly different in the unstimulated group and at 100 nM,
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10 nM and 1 nM concentration of calpeptin. All of the- subtypes were significantly
different than the no cytokine bias group at all of the concentrations of calpeptin
tested figure 16.

99

0002.....------------- - -- -- - - - - - - - - -- -- - - - No qltokine· bias
.. O ··T 1

-.tr- rh2

-tt,- Th17
0,00 15 ~---------_ ____,A'--+__----:;;~~___Ir__-____.:J:....-------

O , 0005 ~-----------------------~r__~~-

O ~-----~~-----~------~--~--~--~-~
Unstll11Ula ed

St imu lated

10uM

1uM

100nM

10nM

1nM

iOOpM

10pl,,'

1pM

Stimulated + Calpeptin Concentration
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Figure 18: Th Subtype Proliferation with Calpeptin Compared to Each
Other. A comparison of the proliferation of all of the subtypes of Th cells
responsive to MBP Ac1-8 as measured by 3H-thymidine uptake when stimulated
with MBP Ac1-8 peptide in the presence of various concentrations of the calpain
inhibitor calpeptin divided by subtype. A, compares the proliferation of Th1
biased cells to Th2 biased cells at each data point. B, compares the proliferation
of Th1 biased cells to Th17 biased cells at each data point. C, compares the
proliferation of Th2 biased cells to Th 17 biased cells at each data point. Mean ±
SEM (n = 3). *, P < 0.05 between groups at the same treatment point.
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The Effect of Calpain Inhibition on Th Cell Cytokine Profile
A more extensive secreted cytokine profile of the E3 MBP specific cell
culture stimulated with the native 4K MBP peptide is presented in figure 19. The
cytokines were assessed with an immunoblot array to more specifically classify
the T helper cell subtype profile that the E3 cells represent and also to determine
if there was any alteration of the cytokines produced when calpeptin was present.
Figure 19 is a comparison of the relative cytokine presence compared to the
array's positive spots for a media control, a culture stimulated with MBP Ac1-8
after 2 days and 7 days. Figure 19 also compares the cytokines present 2 days
after restimulation in the presence of 100 J.,IM of calpeptin. As far as profiling the
cytokines from E3 cells are concerned for T helper cell subtype categorization,
the cells secrete GM-CSF, IL-3, IL-5, IL-6, IL-13, MCP-1, MIP-2 and RANTES.
Comparing the Day 2 culture sample to the Day 7 culture sample the only real
difference is with IL-3 which is decreased by Day 7 to almost control levels. The
effect observed when comparing the 100(JM calpeptin culture to the stimulated
culture is mainly a decrease of secreted cytokines. The degree to which these
cytokines are decreased is the major difference between them. The cytokines
that are decreased 20%

or less are IL-5, IL-13, MIP-2 and RANTES.

The

cytokines that are decreased 20% or greater are GM-CSF, IL-3, IL-6, MCP-1.
The Th subtype that these cytokines most closely resemble is of a Th2 subtype.
The cytokine profile does not fit a Th2 cytokine profile completely but due to the
fact that this is a cell line and not a primary culture a slight variation is not
surprising.
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Figure 19: E3 Cell Cytokine Profile. The cytokine profile of MBP Ac1-11 specific T cells
stimulated with the native MBP Ac1-11 (4K) peptide as measured by an immunoblot
cytokine array. The cytokine levels are relative to a positive spot present on the
immunoblot. The samples tested were a media control, the supernatant 2 days and 7 days
after restimulation of the cells with 4K MBP Ac1-8, and the supernatant 2 days after
restimulation in the presence of 100 JJM of the calpain inhibitor calpeptin. The bars
represent the mean of several spots for each cytokine.
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The cytokine profiles were also assessed using ELISA to focus on the
specific cytokines of interest. Early experiments painted in the direction of a Th2
type cytokine profile for the E3 cells so that became the focus. The supernatant
from the proliferation assays was sampled at 24 hours after plating of the
experiment as described in the methods section and these samples were used
for the ELISA experiments. Figure 20 is the IL-4, 10, 12 and IFN-y levels for the
various groups comparing calpeptin concentrations to the unstimulated and
stimulated groups without calpeptin exposure. Significant differences comparing
the unstimulated and stimulated controls to the calpeptin groups are observed in
the Th2 cytokines IL-4 and IL-10. All of the IL-10 levels were significantly
different than the unstimulated control. The IL-10 level was significantly lower in
the 100 IJM and 1 OJJM calpeptin groups compared to the stimulated group with

no calpeptin. The Th1 cytokines, IFN-y and IL-121 were extremely low for all of
the groups tested and no significant difference between groups was observed.
The cytokine profile for the E3 MBP specific T cells with different
stimulating peptides was also assessed in the context of calpain inhibition (figure
21A and 218). The cytokine profile was assessed without stimulating with MBP
to assess the effects of calpain inhibition in the absence of stimulation.

The

profile was also assessed when the cells were stimulated with the native MBP
Ac1-8 peptide (4K) to determine the cytokine profile and the effects of several
concentrations of calpain inhibitor on these cytokines. The cytokine profile was
also measured when using a strong agonist, the MBP Ac1-8 with an alanine
substitution at position 4 with several concentration of calpeptin. The cytokine
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profiles for IL-4 and IL-10 for these various stimulation paradigms are presented
in figure 21A and 21B. The only significant difference observed was between the
4K stimulated groups with 10 nM of calpeptin present and the control and vehicle
groups.
Figure 22 displays the IL-4 and IL-10 levels produced by the E3 cells used

in the proliferation experiment from figure 15, performed with a wider range of
concentrations of calpeptin.

The IL-10 levels were significantly higher for all

groups compared to the unstimulated control. The IL-4 levels were significantly
higher than the unstimulated control in the stimulated group and the 100 nM, 10
nM and 100 pM calpeptin groups. The IL-4 and IL-10 levels were significantly

lower in the 100 ~M calpeptin group compared to the stimulated group with no
calpeptin.
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Figure 20: Calpeptin Alters T Cell Cytokines. Cytokines produced by MBP
Ac1-11 specific T cells when stimulated with the native MBP Ac1-11 (4K) peptide
in the presence of several concentration of the calpain inhibitor calpeptin. Mean
± SEM (n = 3).
*, P < 0.05 vs unstimulated control; t, p < 0.05 vs stimulated
control group.
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Figure 22: Th2 Cytokines in Response to Calpeptin. Cytokines produced by
MBP Ac1-11 specific T cells when stimulated with the native MBP Ac1-11 (4K)
peptide in the presence of a various concentrations of the calpain inhibitor
calpeptin. Calpain inhibition significantly reduced the cytokine expression at the
highest concentrations of calpeptin.
Cytokine expression was significantly
greater than the unstimulated control for all of the concentrations tested with
respect to IL-10 and greater than unstimulated control for the 100 nM, 10 nM and
100 pM groups with respect to IL-4. Mean ± SEM (n = 4). *, P < 0.05 vs
unstimulated control; t, p < 0.05 vs stimulated control without calpeptin.
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The unbiased cytokine profile of the primary lymphocytes from MBP
inoculated mice was measured with the immunoblot cytokine array and is
displayed in figure 23.

These are the cytokines secreted when the cells are

stimulated with MBP Ac1-8 without being biased with exogenous cytokines or
neutralizing antibodies. The hallmark cytokines present in relative high amounts
are IL-6, IL-12p40 (a component of both IL-12 and IL-23) and IFN-y.

These

cytokines mainly indicate that the cells are of an inflammatory profile.
The cytokine profiles of the primary biased cells were also determined
from supernatant samples that were taken from the proliferation experiments.
Figure 24A are the IL-2 levels of the various subtypes when exposed to a range
of calpeptin concentrations.

Figure 24B are the IFN-y levels of the various

subtypes when exposed to a range of calpeptin concentration. Figure 24C are
the IL-10 levels of the various subtypes when exposed to a range of calpeptin
concentration. Figure 24D are the IL-17A of the various subtypes when exposed
to a range of calpeptin concentration.

Several of the cytokines could not be

accurately assessed from alJ of the subtype groups because that specific
cytokine was exogenously added to favor the proliferation of one of the various
subtypes, for instance IL-4. The unbiased group was assessed for IL-4 levels to
determine if they changed in response to various concentration of calpeptin. The
levels of IL-4 from the unbiased group of primary cells stimulated with MBP Ac1-

8 when exposed to various concentrations of calpeptin was not significantly
different than the controls (data not shown).
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cytokines mainly indicate that the cells are of an inflammatory profile.
The cytokine profiles of the primary biased cells were also determined
from supernatant samples that were taken from the proliferation experiments.
Figure 24A are the IL-2 levels of the various subtypes when exposed to a range
of calpeptin concentrations.
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subtypes when exposed to a range of calpeptin concentration. Figure 24C are
the IL-10 levels of the various subtypes when exposed to a range of calpeptin
concentration. Figure 24D are the IL-17A of the various subtypes when exposed
to a range of calpeptin concentration.

Several of the cytokines could not be

accurately assessed from all of the subtype groups because that specific
cytokine was exogenously added to favor the proliferation of one of the various
subtypes, for instance IL-4. The unbiased group was assessed for IL-4 levels to
determine if they changed in response to various concentration of calpeptin. The
levels of IL-4 from the unbiased group of primary cells stimulated with MBP Ac1-

8 when exposed to various concentrations of calpeptin was not significantly
different than the controls (data not shown).
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Figure 23: Unbiased Lymphocyte Cytokine Profile. The various cytokine levels from primary
lymphocytes obtained from a MBP inoculated animal and stimulated with MBP Ac1-B (4K) for 48
hours. These primary cells were not potentiated with exogenous cytokines or neutralizing
antibodies. The cytokine levels are relative to a positive spot present on the immunoblot. The
primary cytokines of interest are IL-6, IL-12p40 and IFN-y indicating the cell type present was
primarily an inflammatory Th 1 subtype. The bars represent the mean of several spots for each
cytokine.
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Figure 24: Th subtype cytokines with calpeptin present. A comparison of the
cytokine production of all of the subtypes of Th cells as measured by ELISA
assay when stimulated with MBP Ac1-8 peptide in the presence of various
concentrations of the calpain inhibitor calpeptin. The cytokine profiling was
performed to determine if calpain inhibitor was having any effect at various
concentrations on the cytokine production. A, compares the production of IL-2
for the various subtypes. B, compares the production of IFN-y for the various
subtypes. C, compares the production of IL-10 for the various subtypes. D,
compares the production of IL-17A for the various subtypes. Mean ± SEM (n =
3).
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Figure 24: Th subtype cytokines with calpeptin present. A comparison of the
cytokine production of all of the subtypes of Th cells as measured by ELISA
assay when stimulated with MBP Ac1-8 peptide in the presence of various
concentrations of the calpain inhibitor calpeptin. The cytokine profiling was
performed to determine if calpain inhibitor was having any effect at various
concentrations on the cytokine production. A, compares the production of IL-2
for the various subtypes. B, compares the production of IFN-y for the various
subtypes. C, compares the production of IL-10 for the various subtypes. D,
compares the production of IL-17A for the various subtypes. Mean ± SEM (n =
3).
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The Effect of Calpain Inhibition on STAT Protein Levels
Calpain does appear to play some role in the T helper cell bias but exactly
where in the activation cascade is still unclear.

In order to further determine

where calpain may be playing a role through assessing the status of the various
STAT signaling molecules which are known to playa role in the T helper cell
subtype activation and proliferation by activating specific transcription factors that
potentiate the various subtypes.

This was assessed mainly though western

blotting of the whole cell Iysates of E3 cells following exposure to various
activating stimulus and various concentrations and types of calpain inhibitors.
STAT 1 and STAT4 are more important for Th1 subtype activation and
proliferation and STAT6 is more important for Th2 subtype activation.
25A are representative blots the 91kD STAT 10 , 84kD

STAT1~,

Figure

89kD STAT4,

110kD STAT6 and 42kD J3-actin proteins. The bar graph in figure 258 represents
the mean densitometry of the bands relative to the control band for several
experiments. There is no significant difference observed between the STAT1
and STAT4 protein levels for any of the groups tested. The STAT6 bands from
the stimulated group and the stimulated groups with 10

~M

and 1 IJM of calpeptin

are significantly higher than the unstimulated control group. The STAT6 protein
level from the 100 IJM calpeptin groups is significantly lower than the stimulated
control group. This may be due to the high level of calpain inhibitor affect a cell
cycle mechanism and arresting a majority of the cells in a phase with low levels
of STAT6 protein.
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Figure 25: The Effect of Calpeptin on STAT Protein Levels. Changes in
various STAT proteins in MBP Ac1-11 specific T cells following stimulation with
MBP Ac1-8 and various concentration of the calpain inhibitor calpeptin. A,
representative blots showing 91 kD STAT 10, 84kD STAT1~, 89kD STAT4, 110kD
STAT6 and 42kD ~-actin. B, Densitometric analysis showing percent change in
the various STAT proteins relative to the unstimulated control group set at 100.
Mean ± SEM (n = 4).
*, P < 0.05 vs unstimulated control; t, p < 0.05 vs
stimulated group without calpeptin.
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Figure 26: The Effect of Calpeptin on Transcription Factor Protein Levels.
Changes in the T-bet and GATA3 transcription factors in MBP Ac1-11 specific T
cells following stimulation with MBP Ac1-8 and various concentration of the
calpain inhibitor calpeptin. The Ca 2+ + lonomycin group is a positive control
group to contrast calpain activation to calpain inhibition. A, representative blots
showing 62kD T-bet, 50kD GATA3 and 42kD ~-actin. B, Densitometric analysis
showing percent change in the T -bet and GATA3 proteins relative to the
unstimulated control group set at 100. Mean ± SEM (n = 3).
*, P < 0.05 vs
unstimulated control; t, p < 0.05 vs stimulated group without calpeptin.
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Figure 27: The Effect of Calpeptin on Transcription Factor Protein Levels in
Jurkat T Cells. Changes in the T-bet and GATA3 transcription factors in Jurkat
T cells following stimulation with a-CD3 or Ca 2 + and lonomycin (Calion) and in
the presence of the calpain inhibitor calpeptin. A, representative blots showing
62kD T-bet, 50kD GATA3 and 42kD ~-actin. B, Densitometric analysis showing
percent change in the T-bet and GATA3 proteins relative to the unstimulated
control group set at 100. Mean ± SEM.
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The Effect of Calpain Inhibition on Transcription Factor Localization
The lack of a clear cut strong significant difference in the transcription
factors and STAT molecules in the E3 cell line using western blotting lead us to
attempt to determine if the proliferative effect observed in Th2 cells by calpain
inhibition was not due to just changes in protein levels but due to localization of
the proteins in the cell. The signal for proliferation and activation comes from
surface receptors on the T cells and must travel to the nucleus in order to
activate the necessary transcription factors. Fluorescent immunohistochemical
staining was used to assess the subcellular localization of STAT 1, STAT6, T-bet
and GATA3 following stimulation with MBP Ac1-8 (4K). The localization was also
assessed following exposure to several concentrations of calpain inhibitor.
Figure 28A demonstrates the staining of STAT1 in green and T-bet in red for the
various groups; control, stimulated, 10

~M

calpeptin and 1 J..IM calpeptin. The

nuclei of the cells are stained blue with DAPI to aid in determining cytoplasmic or
nuclear localization. The cells demonstrated are typical of the staining observed
in the whole culture. There does appear to be a difference between the staining
of the control and stimulated cells. The stimulated cells display a more punctate
staining pattern compared to the control cells which demonstrate a more diffuse
staining pattern restricted to the cytoplasm. Both of the calpain groups
demonstrate cells with increased T-bet staining that seems to either surround the
nucleus or reside in the periphery of the nucleus. Figure 288 demonstrates the
staining of STAT6 in green and GATA3 in red for the various groups; control,
stimulated, 10 IJM calpeptin and 1 IJM calpeptin. The control and stimulated
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groups appear to demonstrate similar staining patterns. Both of the calpain
groups demonstrate cells with increased GATA3 staining that seems to either
surround the nucleus or reside in the periphery of the nucleus.
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Figure 28: IHC Staining for Transcription Factor Localization.
Representative images of MBP Ac1-11 specific T cells stimulated with MBP Ac18 peptide for 48 hours and then stained with immunohistochemical techniques for
A, STAT1 and T-bet and B, STAT6 and GATA3. The nucleus of the T cells was
stained with DAPI. In both staining paradigms the calpeptin treated groups
demonstrate a larger percentage of cells staining positive for the transcription
factors T -bet and GATA3 compared to untreated control and untreated
stimulated group. n = 3 for all treatment and staining groups.
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DISCUSSION
Calpain is a protease involved in a multitude of cellular processes in many
cell types. Research in our lab on calpain inhibitor in the EAE model of MS has
demonstrated a reduction of clinical signs and disease severity with treatment.
The clinical signs and relapse are reduced in an adoptive transfer model of EAE

in which the primed T cells were exposed to calpain inhibitor before transfer to
the susceptible animals.

The mechanism for this reduction is explored in the

chapter. From the current study calpain appears to act as a negative regulator of
Th2 cells through the cleavage of STAT6.

Calpain is also known to be

upregulated in activated Th1 cells before the onset of clinical disease (Shields et
al. 1999a). Therefore the balance of calpain activity probably plays a role in Th

cell bias in response to immune challenge contributing to the proper immune
response.
The hypothesis is that calpain plays

a role in Th subtype bias and

potentiation of the Th2 subtype is tested in the following chapter through
proliferation studies, cytokine profiling and protein level examination in MBP Ac111 specific T cells and in primary lymphocytes isolated from MBP primed
animals.
The CD4+ MBP Ac1-11 T cell line, as determined by flow cytometry (data
not

shown),

demonstrated

an

increased

proliferation

when

various

concentrations of calpain inhibitor were included in the assay (figure 14 and 15).
This proliferative potential was observed both in the presence and absence of
stimulation in figure 14. The effect was not significant when the cells were not
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stimulated with their antigen but the trend was apparent in figure 14B. A DMSO
control was included in this experiment because T cells increase proliferation in
response to sulfoxide compounds. The DMSO was the solvent for calpeptin so it
was also included in any stimulated group at the same concentration to allow for

an accurate comparison proliferative effects due solely to calpeptin. The effect of
calpain inhibition on proliferation was more pronounced and significant during
stimulation providing evidence that calpain signaling may act in the activation
pathway of this type of Th subtype. This experiment with different methods for
activating the MBP Ac1-11 specific T cells also demonstrated that overactivation
can drown out the proliferative effect seen with the calpain inhibitor. The native
peptide was used for stimulation even though the proliferation and cytokine
section (figure 21) were more pronounced with the strong agonist MBP Ac1-11

(4A).
In order to confirm the proliferative effect observed with calpain inhibition,

the proliferation assays were expanded to include a larger range of calpeptin
concentrations (figure 15) to determine if the proliferation would come back to a
stimulated baseline when the concentration of calpain inhibitor was greatly
reduced. Figure 15 demonstrates a nice dose dependent proliferation response
to the calpain inhibitor calpeptin. This assay was also performed with several
other varieties of calpain inhibitors including SNJ6017 and PD150606 which
target the active site and calcium binding site respectively.

Proliferation was

observed but the dose dependent response was not always readily reproducible
(data not shown). This MBP Ac1-11 T cell line only one Th cell subtype, so to
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test if the calpain inhibitor effect was also applicable in the other Th cell subtypes
primary lymphocyte cells were utilized.
The same procedure is used to create the pathogenic T cells for the
adoptive transfer EAE model and the primary cells utilized in this chapter. The
primary cells did not demonstrate any alterations in properties with regards to
calpain inhibitor exposure if they were just stimulated with antigen, therefore
cytokines and

neutralizing antibodies were

utilized to enhance subtype

proliferation and increase the effect observed with calpain inhibitor. Biasing was
also utilized to isolate the effect in the specific subtypes. Figure 16 demonstrates
the subtypes together and demonstrates the necessity of biasing treatment in
order to detect proliferative changes with this assay.

Figures 17 and 18

demonstrate the distinctly different proliferative profiles observed in the Th
subtypes with various calpeptin concentrations.

The profile of figure 178 is

strikingly similar to figure 15 which increases the evidence that calpain plays a
role in Th2 cell subtype as well as increasing the evidence that the MBP Ac1-11
specific cell line is of a Th2 subtype lineage. Recently the importance of Th17
cells in the pathogenesis of EAE has been demonstrated and the decrease in

Th17 subtype proliferation (figure 17D) is another potential mechanism by which
calpain inhibitor decreases EAE disease.

The primary cell subtypes were

compared to each other (figure 18) in order to demonstrate that the significance
of calpain inhibition on proliferation varies by subtype.

The proliferation is

important for the cell to become the dominate subtype but cytokines also playa
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role in the inflammatory environment present during an immune reaction, so they
were also explored in the context of calpain inhibition.
In order to further characterize and identify the subtype of the E3 MBP
Ac1-11 specific T cell a cytokine array was performed (figure 19). There are
extraneous cytokines present but the specific cytokines IL-5, IL-6, and IL-13 for a

Th2 subtype are present in the stimulated group.

The media control was

performed because the media contains FBS which is known to contain some
cytokines.

The calpeptin treated group does not have any cytokines that are

upregulated compared to the stimulated control; in fact, every cytokine is reduced

by a sizeable amount which is probably due to the fact that the calpeptin
concentration is 100 J.JM. At this concentration there was an observed significant
decrease of cytokines as measured by other assays as well (figure 20 and figure
22). This array does add evidence to the fact that E3 MBP Ac1-11 specific T
cells are of a Th2 lineage and therefore place the proliferation assays into
context with regard to calpain inhibition and their proliferative potential. Figure 20
demonstrates that the amount of Th1 cytokines, IFN-y and IL-12 are extremely
low with the E3 cells. This figure also shows that calpeptin produces a significant
decrease of cytokines at higher concentration probably related to nonspecific cell
cycle effects, reinforcing the importance of low dosing, as described in chapter 5.
The supernatant from the proliferation assays that were performed on the MBP
Ac1-11 specific T cells with various peptides (figure 14) was also assayed for
cytokine concentration (figure 21). There was no significant difference observed
with IL-4 and the only significant difference observed with IL-10 was with the
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group exposed to 10nM calpeptin as seen in figure 21A and 218. This lack of
significant difference had more to do with the number of viable cells present in
the experiment as significance is observed with the same cell type and for the
same cytokines in figures 20 and 22. Again the graded response is observed
with the native 4K MBP peptide stimulation (figure 21 B) compared to the 4A
strong agonist which results in a lot more cytokine but not a graded response.
Figure 22 again demonstrates that calpeptin can significantly reduce the cytokine
secretion at higher concentrations but does not significantly increase the
secretion at the concentrations that increase proliferation. The pathogenicity of
the E3 MBP Ac1-11 specific T cells was also tested in vivo by attempting to
induce EAE following an adoptive transfer protocol on mice with an intact
immune system as well as sublethally irradiated mice with an impaired immune
system. In both instances the E3 cells failed to transfer an EAE disease profile
(data not shown).
This cytokine observation was repeated in the primary cell cultures in
which the cytokines were measured. Figure 24 demonstrates that the subtypes
are in fact becoming the dominate subtype in their respective cultures by the
profile measured.

However, calpain inhibitor treatment does not produce any

significant alteration at most of the concentrations tested. Several of the subtype
cytokines that would have been interesting to test and were tested in the E3
cells, such at IL-4, could not be tested in the primary culture because exogenous
cytokine was added as part of the assay. The biasing protocol was substantiated

by figure 23 which demonstrates the cytokine profile of an unbiased culture and
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contains IL-6, IL-12p40 and IFN-y at higher amounts indicating a predominately
inflammatory cell type or either Th1 or a priming to Th17. While these assays
reveal that calpain is involved with Th cell bias they do not shed significant light
on the possible mechanism.
secretion is preserved.

They do, however, demonstrate that cytokine

The preservation of cytokine secretion at stimulation

levels is important in order to maintain proper T cell function and the proper
inflammatory environment.

The cytokine profile is reinforced by cytokines

binding to receptors that activate STAT molecules which in turn transcribe
cytokine loci to further strengthen a subtype.
Calpain in known to act upon several of these STAT molecules so the
proliferative and cytokine effects observed in these MBP specific T cells by
inhibiting calpain activity may be related.

The levels of STAT proteins in the

whole cell lysate were examined following activation in the presence of several
different concentrations of calpeptin. The effect of reduced cytokines (figure 22)
observed at the highest concentration of calpeptin is repeated with the STAT
protein levels at the highest concentration of calpeptin compared to the
stimulated control (figure 258). The level of STAT1 and STAT4 trend lower but
the level of STAT6 is significantly lower compared to the stimulated control. This
reduction in STAT protein levels at the highest concentration of calpeptin is
probably due to non-specific cell cycle effects and the arrest of the cells in a
phase in which the STAT proteins exist at a lower level.

The two lower

concentrations of calpeptin (10IJM and 11JM) however result in STAT6 levels that
trend higher than the stimulated control and are significantly higher than the
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unstimulated control. This is in contrast to the highest calpeptin concentration.
This result supports the hypothesis that calpain contributes to subtype bias
through STAT6.

This also correlates with the proliferation assay (figure 15)

where proliferation of the E3 cells is increased at 10JJM and 1JJM calpeptin.
If calpain is acting to repress the Th2 subtype through cleavage of STAT6
and calpain inhibition results in increased proliferation of a Th2 subtype as seen
in figure 15 and 17C as well as increased STAT6 protein levels (figure 25) it
follows that the transcription factors downstream of STAT6 may be increased as
well.

This notion was explored by western blotting of the E3 MBP Ac1-11

specific T cells to examine the levels of transcription factors T-bet (Th1) and
GATA3 (Th2) following stimulation in the presence of various concentrations of
calpain inhibitors. There was a significant increase of T-bet and GATA3 protein
levels in the groups exposed to the highest calpeptin concentration

(100~M)

compared to the unstimulated and stimulated controls (figure 268). This trend is
also observed in the in vivo studies in chapter 5 where the transcription factors
tend to be present at higher levels in the groups that were treated with high levels
of calpain inhibitor (figure 34). The reason why T-bet follows a somewhat similar
trend to GATA3 can be ascribed to the idea that the protein levels may be
controlled in some way by the activity of proteases in the cells. The activity and
involvement of the protein to carry out its role of transcription and increasing
certain cytokine concentrations may lie with a different signaling mechanism.
The expected trend is displayed in figure 27 which depicts levels of T-bet
and GATA3 in activated CD4+ Jurkat T cells in the context of calpain inhibitors.
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The T-bet level in the activated groups is higher than the protein level in the
activated plus calpeptin group. The GATA3 level in the activated groups is lower
than the protein level in the activated plus calpeptin group.

This trend is

consistent with the hypothesis that calpain activity correlates with Th1 subtype

and calpain inhibition correlates with Th2 subtype by influencing transcription
factor levels. Unfortunately, the western blotting data from the E3 cells does not
correspond to the Jurkat cell data. The whole cell protein levels do not reveal the
entire story so the localization of the STAT proteins and transcription factors
following stimulation and exposure to calpain inhibitors was also examined.
The subcellular localization of the STAT proteins and transcription factors
was an effort to determine if the location in the cell of these proteins played a
more important role than just the quantity of the protein themselves. Figure 28
reveals increased staining for both transcription factors in the groups that were
incubated with calpeptin, especially in the case of GATA3 (figure 288).

The

transcription factor staining also appears more perinuclear in the stimulated cell
groups compared to the unstimulated control group.

This fits with the

mechanism that a transcription factor would move to the nucleus in order to
accomplish its task when the cell becomes activated. The STAT proteins also
display a more punctuate staining pattern in the stimulated groups compared to
the unstimulated control which stains more diffuse through the cytoplasm. This
pattern would correspond to increased concentrations of the protein at cytokine
loci within the nucleus.
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To summarize, the evidence and observations support the hypothesis that
calpain is involved with Th cell bias as observed in 3 different cell systems as
well as in some of the in vivo work that will be presented in chapter 5.

Calpain

inhibition increases the Th2 subtype by increasing prOliferation but not by
increasing cytokine secretion. The mechanism by which this occurs may be due
in part to involvement of calpain in the STAT protein I transcription factor
signaling pathway.
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CHAPTER FIVE

COMBINED TREATMENT OF EAE WITH
APL AND CALPAIN INHIBITOR

INTRODUCTION

The importance of T cells in the pathology of M8 and EAE was identified
in part by EAE studies in which the disease was caused by adoptively
transferring these cells into na"ive animals which subsequently develop clinical
signs (Ben-Nun et al. 1981). T cells have therefore been the target of much
study in the pursuit of the responsible subtypes. In order to prevent or lessen
disease pathologies treatments to alter the cellular properties have been
developed. Our lab, as well as others, have demonstrated the efficacy of calpain
inhibitors in the reduction of clinical signs and pathologies of EAE (Guyton et al.
2006; Hassen et al. 2006).

Likewise the efficacy of APLs of various myelin

proteins has been demonstrated to reduce the occurrence and severity of EAE
(Leadbetter et al. 1998; McCue et al. 2004; 8milek et al. 1991). APLs of MBP
reached phase II trials as a treatment for M8 (Bielekova et al. 2000; Kappos et
al. 2000) when problems with the treatments overshadowed their efficacy.
Calpain inhibitor treatment has not yet been published in a human trial but
various improved versions have demonstrated somewhat impressive safety
profiles (Inoue et al. 2003).

There are shortcomings regarding solubility, cell

permeability and specificity. Therefore, it is important to consider the feasibility of
multidrug strategies in order to overcome the pitfalls and drawbacks of a single
compound at higher doses, yet capitalize on the desirable properties still present
at lower doses.
The calpain inhibitor used for these studies is ((18)-((((1 S)-1-benzyl-3cyclopropylamino-2,3-di-oxopropyl)amino)-carbonyl)-3-methylbutyl)carbamic acid
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5-methoxy-3-oxapentyl ester (SNJ 1945) provided by Senju Pharmaceutical Co.
(Hyogo, Japan). This compound is a peptidyl a-ketoamide with an amphiphile at
the P3 site in order to increase water solubility, a known problem of calpain
inhibitors (Shirasaki et al. 2005). Since this compound has never been used in
an EAE model, a dosing study was designed assess the utility of SNJ1945 and
attempt to identify an effective oral dose (Oka et al. 2006). This study was also
used to further explore the effects of calpain inhibition on T cell bias and some of
the mechanisms potentially involved with this bias.
In order to bring several of the topics from previous chapters together a
study was designed to assess whether combination therapy with APL and
calpain inhibitor treatment is more effective at preventing clinical disease signs
than either treatment alone.

The 810.PL mouse was chosen because the

antigenic sequence against which this strain mounts an immune reaction is the
same MBP sequence modified in chapter 2, MBP Ac1-8. Although it would be
interesting to test an aza-APL, their effectiveness alone has not yet been
established and would require extensive testing and optimization to select a
candidate APL. Since these experiments are testing the combination of APL and
calpain inhibitor treatment at low dose an APL that had already demonstrated the
ability to reduce EAE signs was selected.
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MATERIALS AND METHODS
Cell Culture
The cell types used for the cytokine studies and western blotting were
B10.PL mouse leukocytes enriched from the spleen. The animals from the dose
study were sacrificed 3 days following the onset of clinical signs and the spleen
was dissected out and ground between fritted glass slides to make a single cell
suspension. The cells were strained through a 70 IJm cell filter (BD Biosciences)
and enriched by gradient centrifugation over Ficoll-Paque PLUS (GE Healthcare,
Piscataway, NJ). The cells were then washed twice and then plated onto petridishes coated with anti-CD3 (Santa Cruz Biotechnology) to provide stimulation to
the T cells through the TCR. The cells are grown in RPMI 1640 (MediaTech,
Inc., Herndon, VA) supplemented with 100/0 FCS (Hyclone, Logan, UT) at 37°C in
a 5%

CO 2 atmosphere (Thermo Fisher Scientific, Waltham, MA).

Cell free

supernatant samples were isolated 48 hours later for cytokine analysis and the
cells were harvested for western blotting. The cells and supernatant were stored
at -80°C until analysis.

EAE Animal Model
Male B1 0.PL-H2 u H2-T18a/(73NS)SnJ mice that were 3-5 weeks old were
purchased from Jackson Laboratories (Bar Harbor, ME), provided water and food
ad libitum, and maintained and used in the proposed experiments in accordance

with the Laboratory Welfare Act and the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.

Mice were allowed to

acclimate to the animal facility for at least 3 days before any experimental
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manipulations were performed.

EAE was induced when mice were about 7

weeks old or in the mass range of 18-20 grams.

To induce EAE, mice were

immunized with (1: 1) CFA containing Mycobacterium tuberculosis H37Ra (10
mg/ml; Difco) and phosphate-buffered saline (PBS) containing guinea pig MBP (1
mg/rnl). Each mouse received 4 s.c. injections, one over each haunch, totaling
400

~I

of the emulsion which contains 400

PBS/CFA alone.

~g

of MBP. Control animals received

At the time of the induction the mice also receive an Lp.

injection of pertussis toxin (Sigma) (200 ng/mouse) and again 48 hours later.
After induction of EAE, all mice were monitored daily for weight changes and
analyzed for clinical signs.

The clinical scores for severity of EAE signs were

based on the following grades: O-no change, 1-limp tailor waddling gait with tail
tonicity, 2-partial hind-limb paralysis, 3-hind-limb paralysis, 4-hind-lirnb paralysis
with front-limb weakness or partial paralysis, 5-quadriplegic or moribund.

Half

number scores were used if the animal was partway between clinical score
criteria levels.

Drug Administration

The following dosing strategy for the SNJ1945 dosing study is based on
doses utilized in a retinal degeneration model (Oka et al. 2006) and administered
at a frequency to fit with the published oral pharmacokinetics (Shirasaki et al.
2005).

SNJ 1945 was suspended 4%

carboxymethyl cellulose (CMC).

(WN) in distilled water containing 0.5 %

The SNJ 1945 was then diluted 1:2 in CMC

serially to obtain the various doses.

Each mouse received 100 IJI of the
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respective dose by oral gavage two times daily beginning 7 days following EAE
induction.

The control and EAE animals received just CMC.

were monitored for mass changes and clinical signs of EAE.

These animals
Animals were

sacrificed three days after the onset of clinical signs in order to isolate the cells in
an acute phase of the disease.
Alternatively, for the combined drug study, the SNJ 1945 was dissolved at
0.1 % in PBS for the 10 mg/kg dose and diluted ten fold to obtain the 1 mg/kg
dose. The dose was given in 200 IJI i.p. every other day starting on day 7 and
continuing through day 21 for a total of 8 doses. The animals were monitored
every day for mass changes and clinical signs through day 35 of the study when
they were sacrificed. The SNJ1945 was given Lp. for this study so it could be
injected together with the APL.
The MBP Ac1-8[4Y] (ASQYRPSQ) was synthesized as described in
chapter two and was chosen because of known efficacy in the H2 u EAE model
system (Leadbetter et al. 1998).
solution at 10 mM.

The APL was dissolved in PBS as a stock

This stock was used to prepare two concentrations either

1.25 mM or 0.5 mM which were used to dose the mice. The mice received 200
IJI of the APL solution resulting in a dose of either 250 nmol or 100 nmol from the
1.25 mM or 0.5 mM solution respectively.

The dose was given in 200 IJI Lp.

every other day starting on day 7 and continuing through day 21 for a total of 8
doses following the protocol established by a previous study (Leadbetter et al.
1998).
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The combined drug groups received either a high combination (10 mg/ml
of SNJ1945 + 250 nmol 4Y) or a low combination (1 mg/ml SNJ1945 + 100 nmol
4Y).

The drugs were combined by diluting the stock APL into the SNJ1945

solution and again the dose was given in 200 J,JI i.p. every other day starting on
day 7 and continuing through day 21 for a total of 8 doses.

Cytokine Analysis
Cytokines were measured on supernatant collected 48 hours following
plating and stimulation on the isolated leukocytes. The cytokines were assessed
using OptlEA Sandwich ELISA (SO Siosciences) and the method is described in
further detail in chapter four.

Western Blotting
The methodology used for western blotting is described in chapter four.

Statistics Analysis
All statistical tests were chosen based on recommendations by Fleming, et a/.,
for analyzing data from EAE studies (Fleming et al. 2005) and performed using
SAS@ statistics software. Overall statistical significance for ordinal data including
median clinical score, day of onset, and cumulative clinical score (total for all
animals within each group) was performed using the Kruskal-Wallis test followed
by the Mann-Whitney-U tests for pair-wise comparisons. The proportion of
animals with an incidence of a clinical score;::: 3 in each group was analyzed
using the Fisher's exact test. The null hypothesis was rejected when p < 0.05.
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RESULTS
EAE Clinical Scores were Reduced by Calpain Inhibitor and APL Treatment
Several clinical parameters are displayed in table 2 from the dose study in
order to establish whether or not SNJ1945 given orally was at all effective in
altering EAE clinical signs or disease pathologies. The incidence of disease is
the number of animals that displayed any clinical signs during the time period of
the experiment. The day of onset is the median of the first day that clinical signs
were observed for animals that did display clinical signs. Animals that did not
have clinical signs were not included in this parameter. The maximum clinical
score is the highest clinical score observed for any animal in the group. The
table is organized by the groups which received the various oral doses of
SNJ1945 compared to control animals and EAE animals without treatment.
The incidence of disease was decreased in all of the treatment groups
compared to the EAE-O group that did not receive treatment. The day of onset of
clinical signs was increased in the 6.25, 25, 50, and 200 mg/kg groups compared
to EAE.

The day of onset was similar to EAE-O in the 12.5 and 100 mg/kg

groups. The maximum disease severity in all of the treatment groups was less
than the maximum disease severity in the EAE-O group.

The assessment of

cumulative clinical score was not possible for this study because the animals
were sacrificed three days after onset of disease signs so a complete disease
profile was not obtained.
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SNJ1945 Dose Study (Time to Disease)

Group

Incidence

Day of Onset

Control
EAE-O
EAE- 6.25 mg/kg
EAE- 12.5 mg/kg
EAE- 25 mg/kg
EAE- 50 mg/kg
EAE- 100 mg/kg
EAE- 200 mg/kg

0/8
18/19 (950/0)
213 (660/0)
113 (330/0)
213 (66%)
213 (66%)
213 (66%)
213 (66%)

N/A
16.4 ± 1.03
22.5 ± 0.41
16
20.5 ± 1.22
20 ± 3.27
15 ± 0.82
23 ± 0.82

Maximum
CS
0
5
2
3
3

4
3

4

Table 2: The summary disease scores for the oral dosing SNJ1945 EAE
experiment. The groups are divided by the treatment dose. The animals were
dosed orally twice daily from day 7 through sacrifice. Animals were sacrificed
three days following the onset of clinical signs. The n value for each group is
indicated in the incidence column.
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Table 3 contains several descriptive disease parameters from the
combined therapeutic study including incidence of disease, the day of onset of
clinical signs, the maximum clinical score observed for the group and also the
mean cumulative score for the group. The mean cumulative score was included
in this experiment because the animals were all observed for the same set period
of time.

The clinical score from each day of the experiment was summed for

each animal for the entire time. The mean was then taken of these scores for
each group to compare to the other treatment groups.
The incidence of disease compared to the EAE untreated group was the
same for the lower dose of SNJ1945 by itself and the highest dose of combined
treatment. The incidence of disease compared to the EAE untreated group was
decreased for the higher dose of SNJ1945, both of the APL groups, and for the
low dose combined treatment. The day of onset for the low dose of SNJ1945
and the high dose of APL compared to the untreated EAE is not different. The
day of onset for all of the other groups compared to the untreated EAE group
was increased. The maximum clinical score for the SNJ1945 was decreased in
the high dose group to a 2 compared to a 4 for the low dose group and a 5 for
the untreated EAE group.

The maximum clinical score was most markedly

decreased in the groups that included an APL as the therapeutic.

The mean

cumulative score is a summation measure that assess overall disease burden
and is only truly accurate in the time course studies where a complete data set
for all animals is available. The 100 nmol 4Y group and the low dose combined
treatment groups were significantly different than the EAE untreated group. The
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other groups demonstrate a marked decrease in the mean cumulative score
compared to the untreated EAE group but were not statistically significant.
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Combined APL and SNJ1945 Study (Time Course Study)

Group

Incidence

Day of Onset

Control
EAE
EAE- SNJ 1945
1 mg/kg
EAE- SNJ 1945
10 mg/kg
EAE-4Y
100 nmol
EAE- 4Y
250 nmol
EAE- SNJ 1945
1 mg/kg
+
4Y 100 nmol
EAE- SNJ1945
10 mg/kg
+
4Y 250 nmol

0/8
18/19 (95%)

N/A
16.4±1.03

Maximum
CS
0
5

Cumulative
CS
0
15.38 ± 4.50

5/5 (1000/0)

17.6±1.69

4

17.4 ± 9.99

1/4 (25%)

21

2

4.37

3/4 (75%)

20 ± 0.86

0.5

0.62 ± 0.31t

2/4 (50%)

18±0.71

1.5

5.12 ± 4.80

0.5

1.25 ± 1.09t

1.5

3.12 ± 0.94

25 ± 3.53

214 (500/0)

4/4 (100 %

)

20.25 ± 0.95

Table 3: The summary disease scores for the combined therapy treatment. The
groups are divided by the treatment dose. The animals were dosed Lp every
other day from day 7 through day 21. The dosing groups are 1 mg/kg or 10
mg/kg SNJ1945 and 100 nmol or 250 nmol MBP Ac1-9 (4Y) or combination of
these. Animals were sacrificed 35 days after induction of EAE. The n value for
each group is indicated in the incidence column. t, p < 0.05 vs EAE.
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As important as summary measures are in evaluating the disease levels to
compare the control and experimental groups, the disease time curves are also
important to assess the profile of the clinical disease. The disease time curve for
the SNJ 1945 dosing experiment does not reveal much information beyond the
summary statistics presented in table 2 because the animals were sacrificed 3
days following the onset of signs so a complete disease profile curve is not
possible. The combination therapy experiment was performed as a time course
experiment so a complete data set exists for all of the days of the experiment
which allows for the creation of figures 29 - 31. Figure 29 is the mean clinical
score of the SNJ1945 doses alone compared to the EAE untreated and control
groups.

Figure 30 is the mean clinical scores of the 4Y APL doses alone

compared to the EAE untreated and control groups.

Figure 31 is the mean

clinical score of the combination therapy groups compared to the EAE untreated
and control groups.
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Figure 29: EAE Clinical Scores for the Calpain Inhibitor Treated Groups.
Mean clinical score of the SNJ 1945 groups compared to the control and EAE
untreated groups for each day following EAE induction. The clinical score was
assessed following the scale described in the methods section and averaged
across the animals in the study group. Each time point represents the mean
clinical score (n =8 for control, n =19 for EAE, n =5 for each SNJ1945 group).
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Figure 30: EAE Clinical Scores for the APL Groups. Mean clinical score of
the MBP 4Y APL groups compared to the control and EAE untreated groups for
each day following EAE induction. The clinical score was assessed following the
scale described in the methods section and averaged across the animals in the
study group. Each time point represents the mean clinical score (n = 8 for
control, n = 19 for EAE, n = 4 for each of the MBP 4Y groups).
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Figure 31: EAE Clinical Scores for the Combined Treatment Groups. Mean
clinical score of the combined treatment groups compared to the control and EAE
untreated groups for each day following EAE induction. The clinical score was
assessed following the scale described in the methods section and averaged
across the animals in the study group. The low combined treatment group
received 1 mg/kg SNJ 1945 and 100 nmol of MBP 4Y and the high combined
treatment group received 10 mg/kg SNJ 1945 and 250 nmol of MBP 4Y every
other day Lp. starting on day 7 post induction and continuing until day 21 for a
total of eight injections. Each time point represents the mean clinical score (n = 8
for control, n = 19 for EAE, n =4 for each combined treatment groups).
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Figure 31: EAE Clinical Scores for the Combined Treatment Groups. Mean
clinical score of the combined treatment groups compared to the control and EAE
untreated groups for each day following EAE induction. The clinical score was
assessed following the scale described in the methods section and averaged
across the animals in the study group. The low combined treatment group
received 1 mg/kg SNJ1945 and 100 nmol of MBP 4Y and the high combined
treatment group received 10 mg/kg SNJ1945 and 250 nmol of MBP 4Y every
other day Lp. starting on day 7 post induction and continuing until day 21 for a
total of eight injections. Each time point represents the mean clinical score (n = 8
for control, n =19 for EAE, n =4 for each combined treatment groups).
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Cytokine Analysis of Activated T cells
In an extension of the hypothesis from chapter 4 that calpain plays a role
in the bias of T cells and that T cells treated with calpain inhibitor will display a
bias toward Th2 cell subtype, the splenic T cells from the SNJ 1945 treated
animals were harvested, activated and assessed for cytokines.

The secreted

cytokines were measured to determine if calpain inhibitor treatment of an animal
resulted in an altered T cell profile. These T cells were not treated with inhibitor

in vitro like many of the previous studies but would have to alter their profile in
vivo in the animal that was receiving the treatment.

Figure 32 and 33 are the

cytokines as measured by ELISA for the various treatment groups.

The EAE

untreated animals were divided into low to moderate disease (clinical score of 02) and moderate to severe (clinical score 3-5) groups due to the significant
differences observed. Figure 32 shows the amounts of the cytokines IL-12p70,
IFN-y and IL-17A for each of the groups. Figure 33 shows the amounts of IL-4
and IL-10 cytokines for each of the groups. The cytokines for figures 32 and 33
were assessed for significance when compare to the control group, the mild EAE
group or the severe EAE group. In figure 32 the IL-12p70 is significantly lower in
the high grade EAE and all of the treatment groups compared to the control
group.

The IL-12p70 level is not significantly different in the EAE low grade

group compared to the control group. Compared to the EAE low grade group
none of the other groups are significantly different. Compared to the EAE high
grade group the control group and the two lowest dose groups of SNJ1945, 6.25
and 12.5 mg/ml are significantly different. The levels of IFN-y are significantly
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higher in the low grade EAE and four highest doses of SNJ1945 compared to the
control group.

The IFN-y levels are significantly lower in the high grade EAE

group compared to control.

The two lowest doses of SNJ1945 are not

significantly different that control.

The low grade EAE group is significantly

different than all of the rest of groups either higher (control, EAE high, 6.25 mg/kg
or 12.5 mg/kg) or lower (25 mg/kg, 50 mg/kg, 100 mg/kg, 200 mg/kg). The IFN-y
level of the high grade EAE group is significantly lower than all of the rest of the
groups. The IL-17A level of the control group is significantly higher than the EAE
(3-5) group and significantly lower than the 6.25 mg/kg, 25 mg/kg and 200 mg/kg
groups. The IL-17A level of the EAE (0-2) group is also significantly higher than
the EAE (3-5) group and significantly lower than the 6.25 mg/kg, 25 mg/kg and
200 mg/kg groups. The high grade EAE (3-5) group has an IL-17A level that is
significantly less than all of the rest of the groups by quite a large amount.
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Figure 32: The Th1 and Th17 Subtype Cytokines for the Various Treatment
Groups in the SNJ1945 Dose Study. The cytokines were measured in the
supernatant from the leukocytes enriched from the spleen and activated with
plate bound anti-C03. The bars represent the mean ± SEM (n = 3 for control, n
= 2 for each of the EAE groups and n = 3 for each the SNJ 1945 treatment
groups). *, p < 0.05 vs control. t, p < 0.05 vs EAE (0-2). ;, p < 0.05 vs EAE (35).
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Figure 33: The Th2 and Treg Subtype Cytokines for the Various Treatment
Groups in the SNJ1945 Dose Study. The cytokines were measured in the
supernatant from the leukocytes enriched from the spleen and activated with
plate bound anti-C03. The bars represent the mean ± SEM (n = 3 for control, n
= 2 for each of the EAE groups and n = 3 for each the SNJ 1945 treatment
groups). *, p < 0.05 vs control. t, p < 0.05 vs EAE (0-2). ;, p < 0.05 vs EAE (35).
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The cytokines displayed in figure 33 are most commonly associated with
the Th2 subtype (IL-4) and Treg subtype (IL-10) even though Th2 will secrete
some IL-10. The IL-4 levels are significantly lower in the high grade EAE group
compared to the control group.

The IL-4 levels in every SNJ1945 treatment

group are significantly higher than the control, the low grade EAE and the high
grade EAE groups. The IL-10 level of the two EAE groups and the 200mg/kg
group are significantly lower compared to the control group. Compared to the
EAE (0-2) group the IL-10 levels of the control and four lowest dose groups are
significantly higher.

The IL-10 levels of the EAE (3-5) group are significantly

lower than the EAE (0-2) group.

The IL-10 level of the EAE (3-5) group is

significantly lower than the IL-10 levels of all of the rest of the groups measured.

Western Blotting of Activated T cells

In an attempt to further elucidate a possible mechanism by which calpain,
or the inhibition of calpain, may be influencing the Th cell type bias the protein
levels of several STAT proteins and transcription factors were assessed by
western blotting.

The samples used for these whole cell Iysates are the

leukocyte enriched cells from the spleen for which the cytokine profile was also
assessed.
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Figure 34: Transcription Factor Protein Levels from the SNJ1945 Dose
Study. Western blotting for determination of 62 kD T-bet, 50kD GATA3, 89kD
STAT4 and 110 kD STAT6 content in activated leukocyte enriched cultures from
spleens of experimental animals following various treatments with SNJ 1945. The
control animal was induced without the MBP present in the CFA, the rest of the
animals were induced as described in the methods and the treatments groups
received SNJ 1945 orally twice per day beginning on day 7 post induction. The
densitometric analysis showing the mean ± SEM percentage change in 00 of the
various protein bands compared to the control group set at 100 % • n = 3 for
control, n = 2 for the EAE group and n = 3 for each the SNJ1945 treatment
groups. None of the bars were significantly different than control.
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Figure 34 is a representation of the mean densitometry of the protein
bands for each of the various treatment groups compared to the control bands
which were set to 100%

•

EAE untreated group.

Unfortunately, while some of the data in figure 34 trends

This data set only included one animal (grade 5) for the

towards a significant difference compared to the control and EAE groups there is
no real significance at these levels. This is somewhat similar to the experimental
observations of the western blotting in chapter four performed on the whole cell
lysate. The trend was to increase the protein levels of the transcription factors
(T-bet and GATA3) at the higher doses of calpain inhibitors when compared to
the untreated or activated groups.
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DISCUSSION

Following the previous studies of potential modifications to autoimmunity
therapeutics

(Chapter

2)

and

mechanisms

involved

with

EAE

disease

pathologies (Chapter 3 and 4) the application of a combination of these two
approaches in an animal model is of great interest. All therapeutic compounds
have side effects or drawbacks applicable to a risk/efficacy treatment paradigm.
Combination therapy is a potential strategy to overcome some of the drawbacks
that have in the past limited the application of various promising therapy
candidates. This specific aim sought to explore the strategy of combining APL
therapy with calpain inhibitor treatment in an EAE model to target several
disease pathways simultaneously with lower doses of each compound.

The

lower doses together were hypothesized to reduce clinical signs more than either
compound alone at a low dose.

The dosing study in Table 2 does show that

there is a delay in onset of disease for most groups and a reduction of disease
maximum severity in the lower dosing groups more so than in the higher dosing
groups.

This is an interesting observation also observed in other experiments

and EAE models that, at the higher doses of calpain inhibitor, there is either no
benefit or an exacerbation of disease. This demonstrates that calpain activity is
important for the proper regulation of the immune system and that high level
inhibition is actually a problem. This demonstrates the difficulty of controlling the
immune system. The observation is actually helpful because complete calpain
inhibition is not required for the best clinical effect and the immune system may
just need a little push in the correct direction to regulate itself. This increases the
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relevance

of

low

level

dosing.

The

involvement

of

calpain

in

the

neurodegenerative component of EAE (Hassen et al. 2008) makes the pairing of
an inhibitor with some other compound that targets the inflammatory component
more directly, such as APLs, an appealing strategy.

Therefore, a study was

performed using the calpain inhibitor, SNJ1945, and an APL of MBP to assess
the effectiveness of combined therapy. Table 3 and figure 30 demonstrate that
the APL appears more effective than the calpain inhibitor in this model system
and at the doses tested but both compounds produced a reduction in clinical
signs, as most thoroughly measured by cumulative clinical score. The combined
treatment group that used the lower doses of SNJ1945 and the APL was the
most efficacious at reducing clinical disease on all of the parameters measured.
The lack of significant difference for more of the treatment groups compared to
the untreated EAE animals is probably due to the low animal numbers. These
studies were performed more as pilot studies and proof of concept so the trend is
important.

Significant differences are probably easily obtainable from these

trends if the n were to be increased for these treatment groups. The combined
treatment at low dose fits well with the idea that the immune system does not
need to be completely suppressed. A benefit could be observed by only altering
the overactive components with a calpain activity above the normal immune
system function.
In order to tie these studies back to the previous chapters the cytokine
profiles were examined from activated leukocytes enriched from the spleen of the
animals in the SNJ1945 dosing experiment. The profile of the peripheral T cells
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has an influence on how inflammation is going to affect the eNS (Bynoe et al.
2007) therefore assessing the peripheral T cell was an important measure of the
disease model. The calpain inhibitor is thought to act at multiple points in the
pathological pathways associated with EAE including, being associated with
inflammatory type cells (Th1 cell types, microglia and macrophages) (Imam et al.
2007; Schaecher et al. 2002; Shields et al. 1998).

Decreasing calpain activity

may reduce inflammatory cells and delay disease or decrease disease burden.
Several of the most important observations made from the cytokine profile
measured from the dosing study (figures 32 and 33) were the extreme reduction
in all cytokines for the severe disease animals. The cytokines for some of the
treated groups also shifted from Th1 and Th17 to more Th2 and Treg types. The
high grade EAE animals tend to lose cytokine secretion.

Future studies may

address whether this is due to a down regulation of inflammatory cells or due to
suppressive Treg cytokines.

This effect may also be due to cell death and

massive organ failure in the high grade animals.

Alternatively it would be

determined if calpain inhibitor treatment is preserving cytokine function in high
grade disease animals and if that has any bearing on recovery of those mice.
The total cell protein levels of STAT4, STAT6, T-bet and GATA3 are
presented in figure 34 compared to the control level set at 100 %
are somewhat disappointing but not really surprising.

•

These results

Their relation to calpain

inhibition in the T cell subtype profile is not entirely clear though it does match the
trend observed in chapter 4.

The results trend toward increased transcription

factors in the higher dosing groups which also agrees with the results observed
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in chapter 4. Perhaps if the number of animals were increased, the differences
may become significant but another mechanism may be at work such as
phosphorylation in the case of STAT proteins or subcellular localization in the
case of the transcription factors. . The results from chapter 4 seem to lend
evidence to subcellular localization and cell cycle regulation to achieve subtype
bias.
The in vivo studies performed for this dissertation support the hypothesis
that treatment of EAE with a combined therapy of APL and calpain inhibitor at
low dose is more effective at reducing clinical disease than either treatment alone
at that low dose. Importantly, the combined treatment is more efficacious at the
low doses than either treatment alone at the higher doses. This represents an
important strategy for exploring treatment options with therapeutics that may
have been mildly effective yet not effective enough to rival conventional therapies
and were therefore discarded.

Addressing the multiple pathological pathways

and mechanisms involved with this complex disease, or any complex disease of
autoimmunity, is a strategy worth further exploration.
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CHAPTER SIX

CONCLUSIONS AND FUTURE DIRECTIONS

SUMMARY

The studies in this dissertation were conducted to test several hypotheses
addressing various therapeutics intended to treat EAE mediated by T cells.
Chapter 2 includes experiments designed to test the feasibility of creating azaamino acid substituted APLs that maintain bioactivity.

The ultimate goal of

testing these APLs was to demonstrate an increased protease resistance in
order to address some of the shortcoming of current APL therapeutics. These
experiments used aza-amino acid substitution to demonstrate the possibility of
creating APLs with increased protease resistance yet maintain properties
necessary to preserve bioactivity and specificity.
This

dissertation

also tested

several

mechanisms to explain the

therapeutic benefit derived from treating EAE animals with calpain inhibitors,
especially focusing on the effects on T cells.

The experiments described in

chapter 3 were designed to test the hypothesis that the Ca 2+ activated protease
calpain was involved with the cellular process of T cell chemotaxis. This was to
further define the role that calpain inhibition was inhibiting the cells from entering
the CNS; a process required for EAE pathology. The hypothesis was tested with
intracellular Ca 2+ analysis, migration assays, and live cell calpain activity assays.
The major finding was that calpain does play a role in T cell migration and this
role is restricted to chemotaxis.
The experiments described in chapter 4 were designed to test whether
calpain plays a role in Th subtype bias and at what level. This hypothesis was
tested with cellular proliferation assays, cytokine analysis and transcription factor

161

examination. The major findings in this chapter were that calpain does playa
role in Th cell bias and seems to exert its greatest influence by negatively
regulating the proliferation of the Th2 subtype. Calpain inhibition increased the
proliferation of this subtype but the concentration of inhibitor needs carefully
control because some calpain activity appears necessary for normal cellular
processes. Inhibiting calpain does not appear to extend to increasing cytokine
secretion but inhibiting activity at a high enough concentration also inhibits
cytokines secretion. Calpain activity does appear to influence Th cell bias though
the STAT signaling pathway and inhibition of activity can increase or decrease
transcription factors depending on the concentration of inhibitor employed. The
localization of transcription factors appears more important than total cellular
protein levels with regards to calpain activity influencing Th cell bias.
The experiments performed in chapter 5 were designed to test the
combination of several therapeutics in the EAE animal model of MS. Clinical
score was monitored following several dosing protocols using the calpain
inhibitor SNJ1945 and an APL of MBP independently and in combination.
Enriched leukocytes from these animals were tested for cytokine secretion and
transcription factor protein levels to determine the in vivo effect of calpain
inhibition on T cells.

The major finding of this chapter was that low dose

combination therapy was more effective than either therapy alone.
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INTERPRETING THE RESULTS

The involvement of T cells in the pathophysiology of MS and EAE are well
established (Chitnis and Khoury 2003; Dittel 2008).

The development of

therapeutics to target these cells has been difficult and the currently approved
therapies that target T cells have potential side effects or are only mildly
successful for long term treatment.

Improving upon promising therapeutics or

illuminating the mechanism by which clinical benefit is derived is therefore
important.
The most direct approach is to target the specific autoreactive T cells. An
approach for targeting these cells is to modify the antigen to produce a desired
immunomodulatory effect. This effect would either, deactivate the pathogenic T
cells, or shift them to a more desirable subtype. APLs have produced promising
results in many different EAE models but had problems in human trials. Chapter
2 contains experiments that attempted to improve on the hypothesized
shortcomings of natural peptide APLs by employing a strategy of including azaamino acids in order to increase protease resistance while still maintaining
bioactivity.

Figure 6 demonstrates that it is possible to make aza-amino acid

substitutions and maintain binding to a MHC II molecule specific for another
peptide sequence. This is an important property for bioactivity because the APLs
need proper presentation to T cells. Figure 7 demonstrates the key property of
aza-amino acid substitution; increased protease resistance compared to the
native peptide sequence. This increase demonstrates that it is possible to alter
the desirable drug characteristics of APLs and potentially address the large
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d9sage requirement for clinical benefit.

The ability to activate T cells is an

important characteristic to assess any antigen modification and figure 8 shows
that T cell activation is still possible through the TCR when an aza-amino acid is
included in the antigenic sequence. The sequences and cellular proteins used in
this chapter relate to the EAE and MS autoimmune disease systems but this
strategy is by no means restricted to MS.

Inclusion of aza-amino acids may

prove beneficial wherever APL therapy is utilized.
Calpain inhibitor treatment has been demonstrated to decrease the
disease signs of EAE. The mechanisms for this observed effect are still being
determined but ubiquitously expressed calpain is known to have many functions
in cells. This dissertation focused on some of the possible disease modifying
mechanisms involving calpain in T cell migration and Th helper cell bias
development and proliferation. Chapter 3 demonstrated that calpain appears to
play a role in T cell chemotaxis.

The cellular calcium levels (figure 9) are

favorable for calpain activity when exposed to T cell recruitment chemokines.
Calpain inhibition reduced the migration of T cells toward CCL2 (figure 100) and
this effect appears restricted to chemotaxis (figure 10A-C) unlike some other
immune cell types (Lokuta et al. 2003). This effect is also apparent in primary
cells (figure 11). Calpain inhibitor treatment reducing EAE signs is potentially
due to the reduced migration potential of pathological T cells entering the eNS
which prevents the inflammatory pathology.
In addition to the role that calpain plays in migration, chapter 4 addresses
the hypothesis that calpain plays a role in Th subtype bias. The CD4+ Th cell
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plays a large role in the pathology of EAE and the development of certain
subtypes favor immunological conditions necessary for pathological sign
development.

If calpain plays a role in this process, then this might be a

contributing mechanism by which administration of calpain inhibitors aids in
clinical signs.

Figures 14, 15 and 17C quite convincingly demonstrate an

increase in Th2 subtype proliferation with calpain inhibition. Th2 cells are known
to secrete cytokines that can counteract the effect of inflammatory T cells and
reduce the inflammatory bias. This effect was observed in several MBP specific
T cell lines as well as in primary MBP Ac1-8 responsive T cells. The proliferation
of Th17 cells (figure 17D), one of the predominately pathological T cells in EAE,
was conversely reduced at calpeptin concentration that caused a positive
proliferation of Th2 cells.

The bias toward Th2 subtype does not appear to

translate into an increase in secreted cytokines (figures 19-24) but the cytokine
levels are maintained at the calpain inhibitor concentrations that produce the
increase in proliferation. This means that the cell type bias can be shifted away
from an inflammatory subtype by favoring the proliferation of Th2 when calpain
inhibitor is present. The caveat of this strategy is that the Th2 subtype tends to
favor B cell assistance and may increase the possibility of antibody creation and
allergic response. This effect would demand careful monitoring in any clinical
trial but the dosing regiment required and the low concentrations necessary
would possibly only act upon pathological cells with increased calpain activity,
and not normal cellular processes. Several hypothesized mechanisms by which
calpain exert its influence upon Th cell bias were tested. Figures 25-28 examine
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the protein levels and cellular localization of transcription factors involved with the
activation of cytokines that aid in the polarization of the subtypes.

These

pathways reinforce the dominant subtype which can influence the surrounding
inflammatory environment. The protein level of T-bet and GATA3 in the in vivo
results as well as the in vitro results (figures 26 and 34) were increased in the
groups treated with the highest concentrations of calpain inhibitor. There was a
decrease in the STAT protein levels (figures 25 and 34) in the same groups.
While this high concentration of calpain inhibitor does not produce the desired
effect of shifting away from an inflammatory cell bias, like the lower
concentrations do, it does reveal that calpain activity plays a role related to the
level of these proteins.

The IHC images in figure 28 demonstrate that the

number of cells predominately staining for T-bet and GATA3 are increased in the
groups that contain calpain inhibitor. This could be due to localization of the
transcription factor toward the nucleus in order to increase the cytokine
production in the Th2 cell and increase cellular proliferation and bias. Another
possible explanation for this observation is that calpain is involved with a cellular
cycle mechanism and the cells become stuck in a phase where more
transcription factor is present in the cell than STAT protein. This possibility would
explain the western blotting protein levels (figures 25 and 26).
The results obtained in Chapter 5 confirm previous observations that
calpain inhibitors can reduce clinical disease signs in EAE animals (Guyton et al.
2006; Hassen et al. 2006). The results also confirm that APLs based on the
antigenic sequence of MBP are capable of reducing clinical signs of EAE. The

166

significant results of this chapter are the reproduction of observations from the in

vitro studies on T cells with regards to cytokine profiles and transcription factor
levels using an orally available calpain inhibitor. In addition these experiments
also demonstrated the feasibility of the concept of lower concentration combined
therapies to treat EAE. This strategy can produce effective clinical results better
than either therapy alone. Targeting multiple pathways is an important strategy
to continue pursuing in the future.

FUTURE DIRECTIONS
The concept of aza-amino acid incorporation into APLs can be taken to
the next level by determining if increasing the number of aza-amino acids in an
APL can further increase the protease resistance and still maintain the
characteristics important for bioactivity such as MHC II binding and T cell
activation.

Furthermore, these APLs could be tested in an EAE model to

determine if they possess the same ability to decrease clinical signs as the
natural peptide APLs.
The examination of the involvement of calpain in T cell processes can go
beyond the observations made in chapter 3 and 4. More mechanistic studies on
cell cycle or Th cell bias development would be an interesting direction to pursue.
Future studies can use transfected or knockout cells to determine more clearly
where in these cellular processes calpain is exerting its effect. An expansion of
the IHe studies in order to look at localization of the transcription factors in real
time would also be an interesting direction to pursue.
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Live cell imaging with

transcription factors tagged with green fluorescent protein (GFP) and exposed to
calpain activators and inhibitors could be performed.
The animal studies have the greatest range of possible future directions to
explore even though they are the experiments that demand the most resources
and time. An expansion on the current experiments performed in chapter 5 to
determine if an altered cytokine profile returns to baseline after cessation of
therapy would be of interest. Also manipulating the dosing concentration and
frequency to determine the minimal effective amounts would be of value. The
proliferation of Th2 subtype observed in vitro should be explored further in vivo
before calpain inhibitors are used in any human studies for any disease as this
has a potential side effect of increased allergic responses. These results may be
minimized by dosing amounts, routes and frequency as well as application but
they need testing.
neurodegeneration

Calpain inhibitors are being explored in the context of
as well,

so the integration of both of the effects,

immunomodulatory and neurodegenerative (which is an active research
component of the lab) should be performed.
CONCLUDING REMARKS

The data presented in this dissertation supports the hypotheses proposed
in the introduction and points the direction toward future studies involving the
effects of calpain inhibitor treatment and APL modification.

APL treatment

research for MS has lost quite a bit of momentum due to some unsuccessful
clinical trials but the specificity of the concept is still sound. Future efforts made
in field of APL therapeutics, either for MS or any other disease for which specific
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peptide therapy may prove effective, would all benefit from strategies meant to
increase the desirable clinical benefit while reducing the potential side effects.
Aza-amino acid substitution, as demonstrated in chapter 2, is one such strategy
that is worth further examination.
The current environment for drug approval by the Federal Drug
Administration in the USA is quite stringent and requires knowledge of possible
side reaction and deleterious clinical effects. The identification of the effects of a
compound, such as calpain inhibitor, that acts upon a protease with a wide range
of cellular processes is important if these molecules are ever to be applied in a
clinical setting. Chapter 3 and 4 identify some of the effects of calpain inhibition
on T cells. Taken in the context of MS, these effects may prove beneficial but
they also hold value in the application of these compounds to treat other
conditions and the immunomodulation that might occur with their application.
Chapter 5 demonstrated that the use of two compounds that act by
different mechanisms is a viable strategy for treating disease.

This chapter

specifically showed that calpain inhibitor and APLs can work together but more
important is the way in which the beneficial effect was achieved.
inhibitors and APLs may have limited

Calpain

use by themselves in treating

autoimmunity, due to broad action or past difficulties, but in combination, they
demonstrate the important concept that mildly effective drugs may hold promise
when logically combined.
The results presented in this dissertation encompass a large variety of
scientific topics but demonstrate the importance of cross disciplinary research.
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This approach allows for the application of concepts that may seem unrelated at
first but prove useful when combined.

This combination allows for rapid

identification of medically necessary research topics as well as the application in
the medical field of promising research results.
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